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ABSTRACT 
It has been almost a century since Pío del Río-Hortega described the microglial cell, proposing it 
to be primarily occupied with phagocytosis of waste products. While this makes up one of its 
functions, we know today that microglia participate in numerous tasks and can interact with and 
regulate all other cell types of the brain. Given this knowledge, it is perhaps not surprising that 
microglia dysfunction has been implicated in a wide range of neurological disorders, including 
diseases of neuroinflammatory (multiple sclerosis), neurodevelopmental (schizophrenia) and 
neurodegenerative (amyotrophic lateral sclerosis and Alzheimer’s disease) character.  
Monocytes are produced in the bone marrow and are released into the bloodstream from where 
they can infiltrate virtually any tissue, either as a homeostatic process to replace the local 
macrophage pool, or as an inflammatory response to tissue damage. Monocytes can engraft the 
central nervous system under various conditions and are historically recognized as the main 
drivers of the demyelinating process that clinically manifests as multiple sclerosis. However, 
given the right signals, monocytes can also integrate into the neural network and become 
permanent residents of the brain. The work presented in this thesis explores how these distinct 
processes are regulated by the cytokine TGF-β.  
Using conditional gene targeting approaches we investigated the role of TGF-β signaling in 
monocytes during autoimmune neuroinflammation as well as during homeostatic replacement of 
microglia after experimental depletion. We demonstrate that, when autoimmune paralysis is 
established, TGF-β suppresses monocyte effector functions including pro-inflammatory cytokine 
production and oxidative damage, which initiates remission of disease. Subsequently, in a 
setting of microglia loss, monocytes required TGF-β to colonize the microglial niche and to 
maintain microglia-like phenotype and function. Abrogation of TGF-β signaling in monocyte-
derived microglial replacements resulted in the spontaneous initiation of demyelination and 
neuronal damage that clinically presented as a progressive and fatal motor disease.  
In summary, our studies provide novel mechanisms by which TGF-β regulates brain 
homeostasis, which are likely deregulated during disease and that could be pharmacologically 
targeted. 
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1 INTRODUCTION 
1.1 TISSUE-RESIDENT MACROPHAGES 
These are exciting days to study macrophage biology! While originally recognized for their 
phagocytic properties (macrophage = big eater, Greek) – a discovery that earned Russian 
zoologist Ilya Mechnikov the 1908 Nobel Prize in Physiology or Medicine – we understand 
today that macrophages can have wide-ranging functions spanning from regulating wiring of 
the brain to controlling our bowel movements. Macrophages are present in virtually every 
organ of the body where they have fundamental functions tailored to the need of the specific 
tissue. A number of historic examples are illustrated in Figure 1.  
 
Figure 1: Some important examples of tissue-resident macrophage populations and their discovery or functional 
description. References: AV-node macrophage1, Langerhans cell2, Microglia3, Kupffer cells4, Ly6Clow 
monocyte5-7, Osteoclast8.  
Ly6C
low
 monocyte 
Identified and functionally characterized by 
Frederic Geissmann lab (2003). Patrols 
the blood and monitors endothelial 
integrity5-7. 
Kupffer cell 
Macrophages that detoxify the 
liver whose discovery is 
accredited to Karl Wilhelm von 
Kupffer (1876), but were 
probably first correctly 
described by Tadeusz Browicz 
(1898)4.  
Osteoclast 
Multinucleated bone digesting 
macrophages discovered by Albert 
Kölliker (1876)8.  
Langerhans cell 
First described by Paul 
Langerhans (1868), who 
thought they were neurons. We 
know today that they are best 
described as epidermal 
macrophages with migratory 
dendritic cell capacity2.  
AV-node macrophage 
Described by Matthias 
Nahrendorf lab to facilitate 
electrical conduction in the 
heart (2017)1. 
Microglia 
First described as part of the ‘third 
element’ by Santiago Ramón y 
Cajal (1913) and later described in 
detail by one of his students Pío 
del Río-Hortega (1919)3.  
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1.2 DEVELOPMENT OF TISSUE-RESIDENT MACROPHAGES 
Three successive waves of hematopoiesis occur during embryonic development and the 
mature circulating immune system is derived from the final definitive wave, which gives rise 
to hematopoietic stem cells (HSC). Although macrophages had been observed in the embryo 
before the generation of HSCs, these were not thought to contribute lastingly to adult 
macrophage populations. With the identification of several distinct organ-specific 
macrophage populations such as brain microglia, splenic red pulp macrophages, Kupffer 
cells in the liver, van Furth and colleagues instead proposed that all macrophage populations 
were continuously derived from circulating monocytes (definitive hematopoiesis in the bone 
marrow), a model they termed the ‘mononuclear phagocyte system’9. This was an impressive 
model if we consider the knowledge available at that time. However, with the advent of 
advanced techniques to trace cellular lineages we have understood that most mature 
macrophage populations are in fact derived from embryonic precursors. Although the exact 
sequence of events is still a matter of research and debate, there is a consensus that the first 
tissue macrophages are derived from erythromyeloid progenitors that arise in the yolk sac at 
embryonic day 7 (E7.0)10,11. During the first wave of hematopoiesis, these yolk sac 
macrophages colonize the entire embryo, including the brain, to generate microglia and all 
other types of tissue-resident macrophages. According to one model, the erythromyeloid 
progenitors subsequently migrate to the fetal liver, give rise to fetal liver monocytes that later 
invade all organs except the brain and dilute the yolk sac derived tissue macrophages12. 
Concomitant with this, fetal HSCs in the aorta-gonad-mesonephros region colonize the fetal 
liver where they establish definitive hematopoiesis but will also seed the fetal bone marrow 
which will generate adult HSCs. One model suggest that these fetal HSCs are the precursors 
of most tissue-resident macrophages13. Another model suggests instead that all tissue resident 
macrophages are derived from yolk sac macrophages and that subsequent waves of fetal liver 
monocytes only minimally contribute to tissue-macrophage pools14.  
These models thus differ on the final composition of most peripheral tissue-resident 
macrophages, but agree that microglia derive only from yolk sac macrophages. This has been 
attributed to the closure of the blood brain barrier (BBB) which occurs before fetal liver 
monocyte colonization of the embryo and prevents their entry into the parenchyma11,15. After 
birth, adult HSC-derived monocytes from the bone marrow will displace embryonic 
macrophages in some organs, as further discussed below. The consequence of this process is 
ontogenic heterogeneity across organs16,17, and the proposed physiological explanation is 
organ growth and accessibility. Organs that remain accessible through the blood will 
continuously recruit macrophage precursors throughout embryogenesis10.  
 
1.3 DEVELOPMENT AND TURNOVER OF MICROGLIA 
In a series of papers published almost 100 years ago, Pío del Río-Hortega described microglia 
as a separate cellular entity from the previously defined neuroglia (astrocytes)3. Using only 
histological techniques Río-Hortega noticed that microglia precursors invaded the brain 
during embryonic development and proposed that they were of mesodermal origin18. Elegant 
studies in the 1990s further suggested that microglial progenitors originated in the yolk sac, 
penetrated the brain in the embryo and proliferated extensively to give rise to the microglial 
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pool19. Final proof was delivered by Florent Ginhoux and colleagues20 in the form of fate-
mapping experiments using Runx1CreER mice to specifically label macrophages in the yolk sac 
at E7.5 which appeared in the brain rudiment at E9.5. This process required a functioning 
circulatory system and was dependent on CSF1R. A more detailed analysis revealed that 
microglia arise from a c-kit+ progenitor with both erythroid and myeloid potential in the yolk 
sac21 (erythromyeloid progenitor). Microglia development was dependent on PU.1, a master 
myeloid transcription factor22, as well as IRF8, and the cells invaded the brain in a manner 
dependent on matrix metalloproteinases but independently of chemokine signaling21. The 
development of adult microglia from erythromyeloid progenitors is a process occurring in at 
least three developmental stages, with each stage characterized by distinct transcriptomes 
driven by unique transcription factors23,24. This supports the idea of distinct functional roles 
of microglia during development vis-à-vis adult homeostasis, which has been experimentally 
observed (see HOMEOSTATIC FUNCTIONS OF MICROGLIA). It was recently 
demonstrated that male and female microglia display striking transcriptional differences, 
which are influenced both pre- and post-natally by the microbiome24. The importance of the 
microbiome for proper microglia development was demonstrated by Erny et al., who found 
germ-free mice to have an immature microglia phenotype which could be restored by 
recolonization with complex microbiota, this being dependent on microbiota-derived short 
chain fatty acids25.  
If homeostatic conditions are maintained, the microglial pool is sustained throughout adult 
life with minimal or no input from definitive hematopoiesis, as demonstrated by long-term 
parabiosis experiments20,26,27. Microglia require constant signaling through the CSF1R for 
survival28, and can use either of its ligands M-CSF20 or IL-3429,30 for their turnover. Several 
recent studies demonstrate that the microglial pool is maintained by coupled proliferation and 
apoptosis31-33, meaning that when one microglial cell undergoes apoptosis, a nearby cell 
proliferates to compensate for the loss. The turnover rates appear to be variable in different 
brain regions, as Tay et al. reported that microglia in the olfactory bulb turn over fastest, 
completing a full cycle every 8 months as compared to 15 months for the hippocampus, and 
as long as 41 months for the cortex32. These slow turnover rates are challenged by another 
study using BrdU incorporation rates and live imaging of microglia that estimated that the 
entire microglial population turned over every 96 days31. A long-term imaging study of 
individual cortical microglia demonstrated that a minority of imaged microglia died over a 
15-month period, indicating that as much as half of the cortical microglial pool may survive 
for the lifespan of a mouse33. Human microglia were estimated34 to have an average life span 
of 4.2 years based on analysis of incorporation of atmospheric 14C.  
 
1.4 OTHER CNS-ASSOCIATED MACROPHAGES 
Microglia are the predominant myeloid cells in the brain during steady-state conditions and 
reside in the parenchyma. However, CX3CR1+ macrophages also line non-parenchymal 
spaces such as the meninges, vasculature and choroid plexus in the adult brain35. Based on 
early bone marrow chimera experiments it was proposed that perivascular macrophages 
originated from adult hematopoiesis36. However, it has subsequently been demonstrated that 
irradiation sensitizes the brain for engraftment by peripheral myeloid cells37, and recent fate 
 10 
mapping and parabiosis studies have revealed that perivascular, meningeal and choroid 
plexus macrophages are all embryonically-derived38. Perivascular and meningeal 
macrophages (CX3CR1+CD45hiCD206+) subsequently self-maintain, whereas choroid plexus 
macrophages (CX3CR1+CD45hi) have a slow turnover from CCR2-dependent peripheral 
monocytes38. These non-parenchymal macrophage populations were more recently shown to 
separate based on CCR2, CD38 and MHCII expression and were suggested to make up as 
much as 10% of the central nervous system (CNS) leukocyte pool, based on high dimensional 
mass cytometry39. The sensitivity of these ‘border-associated macrophages’ to intravenous 
delivery of a CSF1R-specific antibody further confirms their location outside of the BBB. In 
contrast, microglia that reside inside the BBB are not depleted by this treatment39.  
 
1.5 HOMEOSTATIC FUNCTIONS OF MICROGLIA 
Microglia are integral components of the developing brain, being able to promote selective 
death or survival of specific neuronal populations. For example, microglia induce 
programmed death of hippocampal neurons40 and Purkinje neurons41 during development and 
orchestrate their phagocytic removal. Conversely, IGF1 production by microglia supports 
survival of layer V cortical neurons during postnatal development42. Embryonic microglia 
have also been shown to associate with dopaminergic axons and control their outgrowth to 
participate in correct layering of cortical interneurons43. During postnatal development 
microglia promote synaptic pruning44, which is facilitated by the complement system45,46. 
Finally, BDNF production by microglia regulates dendritic spine formation and elimination 
postnatally, influencing hippocampal learning47. These findings identify microglia as a 
central player in sculpting neuronal circuits, failure of which is linked to neurodevelopmental 
disorders such as autism and schizophrenia48.  
Microglia in the uninjured CNS are traditionally described as being ’resting’ or ’quiescent’, 
considered silent sentinels waiting for immune activation or trauma. However, time-lapse 
two-photon imaging in the cerebral cortex of live mice has revealed that microglia are highly 
dynamic cells even in the naive brain49. While microglial cell bodies always remain 
stationary (even beyond a year of repeated imaging33), their processes are constantly 
extending and retracting49, making transient contacts with synapses50. This motility requires 
ATP sensing by purinergic receptors51, several of which are expressed in microglia52. 
 
1.6 MONOCYTE DEVELOPMENT IN THE BONE MARROW 
The development of circulating monocytes occurs from HSCs in the bone marrow. 
Hematopoiesis is classically described as a stepwise process whereby highly proliferative and 
multipotent stem cells differentiate into cells with increasingly restricted lineage potential53. 
This is presented as a tree-model (Figure 2) starting with the HSC and branching out to form 
all the cellular lineages of the blood. According to this model, separation of blood lineages 
starts with the commitment to either lymphoid (common lymphoid progenitor, CLP) or 
myeloid (common myeloid progenitor, CMP) lineages. The myeloid lineage then divides into 
a platelet/erythrocyte-forming branch (megakaryocyte-erythrocyte progenitor, MEP) and a 
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neutrophil/macrophage/dendritic cell (DC) forming branch (granulocyte-macrophage 
progenitor, GMP), which further separates into downstream lineage-committed 
progenitors54,55. The existence of these distinct differentiation states is supported by cell 
transfer experiments. According to this model, circulating monocytes are formed downstream 
of the GMP via the monocyte-DC progenitors (MDP)56 and the common monocyte 
progenitor (cMoP)57. However, recent single cell RNA-sequencing experiments suggest that 
commitment to distinct cellular fates already occurs at the multipotent progenitor (MPP) 
stage, and that intermediate differentiation states with multi-lineage potential are very rare58. 
This was confirmed in vivo by following the fate of individual transplanted hematopoietic 
progenitors, demonstrating that CMPs rarely gave rise to multiple lineages59. This data 
questions the classic tree-model and suggests that CMPs, rather than having multi-lineage 
capacity, are a collection of heterogeneous progenitors with pre-fixed states. Historically, 
CMPs and other progenitor populations have been studied as bulk-sorted populations, which 
could explain the conflicting results. New models incorporating this knowledge are being 
proposed60.  
 
  
Figure 2: The classic model of hematopoiesis starting with a binary choice to commit to myeloid (CMP) or 
lymphoid (CLP) lineages. This model is being revised.  
 
HSC
CLP
CMP
MEP
MPP cMoP
Monocyte
CDP
Megakaryocyte
Erythrocyte
Basophil
MDP
GMP
Eosinophil
Neutrophil
T-cell
B-cell
Dendritic cell
 12 
The commitment to a distinct cellular fate is believed to be determined by a unique 
combination of transcription factors61. For example, monocyte specification relies on high 
expression of the pioneer transcription factor PU.1 combined with the presence and absence 
of specific transcription factor partners, including IRF8, C/EBPα and GFI1. At lower doses, 
PU.1 instead promotes neutrophil development62 and IRF8 and GFI1 at high doses promotes 
monocyte63 or neutrophil64 development, respectively. Co-expression of IRF8 and GFI1 
arrests progenitor cells in a metastable state, each transcription factor promoting one cellular 
fate and inhibiting the other, until one factor prevails, inducing either monocyte or neutrophil 
development65. Individual myeloid lineages are enforced by the action of cytokines, including 
M-CSF and G-CSF, which act at the GMP stage to induce monocyte or granulocyte 
commitment, respectively66. Furthermore, deficiency in M-CSF or G-CSF results in loss of 
the monocyte/macrophage67 and granulocyte68 lineages, respectively. GM-CSF is a more 
promiscuous cytokine, which can support the growth and development of granulocyte, 
monocyte and conventional DC lineages69,70. However, GM-CSF deficiency results in no 
major alterations in the bone marrow, indicating that it is redundant during steady-state 
hematopoiesis71. M-CSF, G-CSF and in particular GM-CSF are significantly induced during 
settings of stress or infection to support the increased demand of mature circulating myeloid 
cells and to imbue them with effector functions. In these settings, the CSFs have been thought 
to act only on downstream progenitors or fully differentiated myeloid cells. However, M-CSF 
was recently shown to act already on HSCs to induce PU.1 expression and initiate myeloid 
lineage commitment and that this was potentiated by bacterial compounds72. 
Monocytes in the circulation exist in two main subsets described respectively as 
CD14+CD16– and CD14lowCD16+ in humans73 and as Ly6Chi and Ly6Clow in the mouse5. 
Ly6Chi monocytes are considered short-lived inflammatory cells with the capacity to infiltrate 
tissues upon inflammation. Ly6Clow monocytes do not enter tissues but instead patrol the 
vessel lumen where they have scavenging functions in the steady-state, and upon 
inflammation they can recruit neutrophils to mediate endothelial cell disposal6,7. These 
observations concord with the idea that Ly6Clow monocytes should be considered terminally-
differentiated, blood-resident macrophages74.  
Ly6Chi monocytes express CCR2 highly, which is required for their exit from the bone 
marrow and entry into the circulation75 in response to a CCL2 gradient produced by 
mesenchymal stem cells in proximity to the vascular sinuses of the bone marrow76. In the 
circulation the steady-state half-life of Ly6Chi monocytes is only 20 hours, and they 
subsequently downregulate Ly6C expression to give rise to terminally differentiated Ly6Clow 
monocytes77. This differentiation process was recently characterized in detail using single cell 
RNA-sequencing, demonstrating this to be a C/EBPβ-dependent pathway occurring through a 
Ly6Cint transitional state78. The gene signature of the Ly6Cint population was characterized by 
high expression of CD209a and MHCII associated molecules, which overlaps with a recently 
identified CD209a+MHCII+ subpopulation of monocytes that preferentially gives rise to 
monocyte-derived dendritic cells (moDCs)79. This stood in contrast to a CD209a–MHCII–
Ly6Chi population of monocytes giving rise to iNOS+ macrophages during microbial 
stimulation79. The potential heterogeneity of the monocyte pool has been further increased by 
the recent finding that a ‘neutrophil-like’ subtype of monocytes develop downstream of 
GMPs in an MDP/cMoP-independent manner. In this study, GMPs and MDPs independently 
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generated Ly6Chi monocytes with distinct gene expression profiles which were differentially 
mobilized from the bone marrow in response to toll like receptor ligands80. Recently, another 
study identified a Ceacam1+Msr1+Ly6C−F4/80−Mac1+ subset of monocytes with bi-lobed 
nuclei that developed directly from GMPs and were specifically involved in fibrosis81. How 
this subset relates to the neutrophil-like monocyte above remains to be clarified.  
In summary, the increased sensitivity of RNA sequencing techniques has revealed increased 
complexity in the monocyte compartment. Whether these subtypes truly represent distinct 
macrophage precursors with different downstream functional properties will require 
additional detailed investigation. At the time of writing, we are thus faced with the possibility 
that the diversity in monocyte progeny can be explained by the existence of distinct monocyte 
subsets with unique differentiation programs, transcription factors and functional capacities. 
Alternatively, and as discussed below, the monocyte compartment is homogenous and 
diversity is dependent on imprinting by the tissue environments. These hypotheses are not 
mutually exclusive.  
 
1.7 MONOCYTE DIFFERENTIATION TO MATURE MACROPHAGE 
POPULATIONS 
1.7.1 Steady-state macrophage populations 
Under steady-state conditions most macrophage populations are sustained without input from 
mature circulating monocytes27,77,82, but notable exceptions exist. Ly6Chi monocytes 
constantly replenish the macrophage pool in the intestine83,84. Macrophages colonize the 
entire length of the intestine and are enriched in the lamina propria close to the epithelial 
layer85 and are thus constantly exposed to commensal bacteria and orally acquired antigens. 
However, despite phagocytic and bacteriocidal ability, intestinal macrophages are 
unresponsive to toll like receptor stimulation in both mouse and Man86,87. This anti-
inflammatory phenotype can be explained, at least in part, by constant IL-10R signaling in 
gut macrophages, abrogation of which leads to colitis88. Exposure to the microbiota, which is 
a defining feature of macrophages in the intestine, likely drives requirement for monocyte 
replenishment. This is supported by the fact that embryonic macrophages are displaced by 
monocyte-derived macrophages during the first weeks after birth, which coincides with the 
time of bacterial colonization of the gut. Furthermore, germ-free mice also have significantly 
fewer intestinal macrophages than do conventionally housed mice84. 
In addition to intestinal macrophages, circulating monocytes slowly replace macrophages in 
the dermis89, the exocrine pancreas90, the testicles91, the peritoneal cavity92 and the choroid 
plexus of the brain38. Replenishment of cardiac macrophages by monocytes has also been 
proposed93 although this is a matter of controversy94-96. Interestingly, several of these 
monocyte-replenished macrophage pools have adjacently located macrophage populations 
which turnover independently of monocytes, including Langerhans cells in the epidermis2, 
macrophages in pancreas endocrine islets89, and microglia as well as perivascular and 
meningeal macrophages in the brain20,38. This proposes the existence of tightly controlled 
microenvironments regulating macrophage turnover in these organs.  
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1.7.2 Infection 
During viral, bacterial, fungal and parasitic infections monocytes are recruited in high 
numbers to the affected organs from the circulation97. One well-studied example is Listeria 
monocytogenes infection, which recruits monocytes in a CCR2-dependent manner to the 
spleen where they differentiate into TNFα- and iNOS-producing macrophages (originally 
called Tip-DCs) that are crucial in combatting the infection75. In the liver, Listeria selectively 
infects Kupffer cells that die by necroptosis, leading to a dramatic drop in their numbers. The 
embryonic-derived Kupffer cell pool is completely replaced by recruitment of monocyte-
derived macrophages and their M-CSF/IL-4 dependent local proliferation. During the early 
stage of infection infiltrating monocytes have an inflammatory profile characterized by high 
expression of IFN-γ that under the influence of IL-4 leads to monocytes adopting a Kupffer-
cell like phenotype to promote restoration of tissue integrity98. γ-Herpes virus infection in the 
lung similarly leads to the selective death and complete replacement of embryonic-derived 
alveolar macrophages with monocyte-derived macrophages. These have a distinct 
transcriptional profile and subsequently protect mice from development of house dust mite 
allergy99. Taken together, these examples demonstrate that bacterial and viral infections can 
dramatically and permanently alter the macrophage landscape in distinct organs, giving long-
lasting effects on tissue homeostasis.  
1.7.3 Sterile tissue injury 
Sterile tissue injury regularly results in monocyte invasion of the affected organ to assist in 
clean-up and to promote a return to homeostasis. For example, skeletal muscle injury causes 
infiltration of Ly6Chi monocytes that differentiate into CX3CR1hi anti-inflammatory 
macrophages that participate in muscle regeneration100. Paracetamol-induced liver injury 
similarly leads to Ly6Chi monocyte recruitment, occurring en masse within 24 hours of injury 
in a CCR2- and M-CSF-dependent manner. These monocytes differentiate into short-lived 
CX3CR1+ macrophages (virtually gone by 120h), contribute to repair of liver damage and 
exhibit a gene-expression profile that is distinct from liver-resident CX3CR1neg/low Kupffer 
cells101.  
Monocytes also contribute to the cardiac macrophage pool during heart disease. An 
experimental model of myocardial infarction results in extensive CCL2-driven102 recruitment 
of Ly6Chi monocytes to the heart103,104. The local ischemia causes apoptosis of virtually all 
F4/80+ resident cardiac macrophages within 24 hours, which are quickly recovered (4 days) 
by the infiltrating monocytes95. Hypertension results in a similar but more limited expansion 
of the heart macrophage pool driven by monocyte infiltration, which can contribute to heart 
failure105.  
Ionizing irradiation is known to condition the brain for engraftment of Ly6Chi monocytes37, 
which has confounded the interpretation of many neurological disease models106. However, 
more recently, it was reported that after irradiation, CNS-recruited monocytes integrate into 
neurogenic niches and participate in brain repair in a G-CSF-dependent manner107. 
Furthermore, a number of acute injuries to the brain cause a robust engraftment of 
monocytes, including stroke108, epileptic seizures109 and traumatic brain injury110,111. The role 
of monocytes in stroke and epileptic seizures appear to be mostly deleterious, although there 
are conflicting reports, as we have reviewed elsewhere112. Traumatic brain injury induced by 
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a controlled cortical impact results in transient accumulation of CCR2+CX3CR1+ 
monocytes/macrophages in the hippocampus that, if inhibited, reduces neuroinflammation 
and alleviates injury-induced cognitive impairment110. Spinal cord injury has been proposed 
to attract both Ly6ChiCX3CR1low and Ly6ClowCX3CR1hi monocytes to the injury site through 
alternate routes which have deleterious or beneficial effects on wound healing and motor-
function recovery, respectively113. In the CNS, whether monocytes contribute long-term to 
the microglial pool after resolution of these disease models is incompletely explored. Taken 
together, these studies indicate that monocytes can have both disease-promoting and -
preventing functions during injury, even in the same organ.  
1.7.4 Experimental depletion 
Experimental depletion of distinct macrophage subsets represents a useful tool to study the 
capacity of local proliferation or monocyte recruitment to compensate for cellular loss. For 
example, when Kupffer cells are depleted in Clec4f-DTR mice, monocytes repopulate the 
liver in one wave, giving rise to fully functional, long-lived macrophages that are 
transcriptionally and phenotypically indistinguishable from normal Kupffer cells114. 
Similarly, cardiac macrophages are replenished completely by monocytes when depleted in 
CD11b-DTR mice95. Furthermore, an empty alveolar macrophage niche as achieved in Csf2r–
/– mice, can be repopulated by adoptive transfer of purified yolk sac macrophages, fetal liver 
or adult monocytes without loss of function or ultimate differences in the transcriptomic 
signature115.  
Depletion of microglia has been achieved in a variety of ways. Using Cx3cr1CreERR26DTR 
mice, Bruttger et al. achieved 80% reduction in the microglial pool, which was rapidly 
compensated for by local hyperproliferation116. A CSF1R antagonist results in even more 
efficient depletion (>99%), which is similarly recuperated by proliferation of the residual 
microglia28,117. If mice are exposed to lethal irradiation, however, the entire microglial pool is 
replenished by circulating precursors116,118, likely Ly6Chi monocytes. While proliferating 
microglia adopt a transcriptional profile more similar to naive microglia, bone marrow-
derived ‘microglia’ remain transcriptionally distinct116. Delivery of gangciclovir to CD11b-
HSVTK mice via an intracerebroventricular cannula results in complete ablation of microglia 
as long as the drug is delivered119. Removal of the drug results in rapid repopulation of 
microglia by peripheral myeloid cells120,121, which remain beyond 6 months and respond by 
extending processes toward ATP120, indicating that peripherally-derived macrophages can 
adopt the microglial purinergic machinery.  
 
1.8 TISSUE MICROENVIRONMENT CONTROL OF MACROPHAGE IDENTITY 
All macrophage populations are seeded from a limited set of progenitors, yet they display 
great diversity both in phenotype and function. The current consensus is that the unique 
microenvironments present in individual tissue niches play a prevailing role in determining 
macrophage identity16,122,123. In fact, tissue-specific differentiation programs are initiated 
immediately after colonization of embryonic tissues by yolk sac-derived pre-macrophages124. 
Tissue-specific transcription factors have been identified for many macrophage subsets, 
including Pparg for alveolar macrophages125, Spic for red pulp macrophages126, Id3 for 
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Kupffer cells124, Runx3 for Langerhans cells127, Gata6 for peritoneal macrophages128,129 and 
Sall1 for microglia118. Evidence of imprinting by the microenvironment was reported after 
adoptive transfer of bone marrow cells into irradiated mice, demonstrating that the tissue-
specific chromatin states in the lung, liver, spleen and peritoneum are adopted by transplant-
derived macrophages130. This study further demonstrated the power of the alveolar 
macrophage niche in reprogramming incoming macrophage precursors; Peritoneal 
macrophages transplanted into the lung were transcriptionally more similar to alveolar 
macrophages than their peritoneal counterparts when retrieved 15 days later130. This is further 
supported by the ability of yolk sac macrophages, fetal liver monocytes and adult bone 
marrow-derived monocytes to recapitulate alveolar macrophage transcription and function 
when transplanted into an empty alveolar macrophage niche115. These findings have spawned 
the recently proposed ‘niche theory’,16 which suggests that the tissue microenvironment 
imprints functionality on the macrophage precursor independently of its origin, provided that 
the niche is accessible and that empty niches are available. Such imprinting would suggest the 
existence of ‘niche signals’ regulating tissue-specific macrophage identity131, which have 
been resolved for some organs but remain the subject of ongoing research. For example, red 
pulp macrophage identity is driven by the transcription factor Spi-C126, which is induced by 
heme, a by-product of splenic erythrocyte turnover132. Peritoneal macrophage-specific 
functions are controlled by retinoic acid, a metabolite of vitamin A produced in the omentum, 
the peritoneum-associated adipose tissue128. Alveolar macrophages require both GM-
CSF125,133 and TGF-β signaling134 which drive PPARγ expression, promoting alveolar 
macrophage survival. TGF-β also maintains the microglia-specific transcriptome135, probably 
by inducing Sall1 transcription118, as discussed in greater detail below.   
 
1.9 TGF-β SIGNALING 
The transforming growth factor (TGF)-β family in mammals includes three members, TGF-
β1, 2 and 3. TGF-βs are synthesized as propeptides containing an N-terminal portion called 
the latency-associated protein (LAP) and a C-terminal domain that is the mature cytokine. 
These are cleaved from each other in the Golgi apparatus by the endopeptidase furin. After 
cleavage and assembly, LAP and the cytokine portion of TGF-β remain non-covalently 
attached. The crystal structure demonstrates that LAP wraps around TGF-β, covering all 
contact sites that could interact with receptors136 and TGF-β can thus be stored inactive in the 
extracellular space. TGF-β can be activated by a number of mechanisms137 of which 
thromospondin and integrins are important in vivo.  
TGF-β  signals via tetrameric receptors composed of two type I receptors (TGFβRI) and two 
type II receptors (TGFβRII), which are both serine/threonine kinases (Figure 3). Upon 
engagement of TGF-β, TGFβRII phosphorylates the cytoplasmic domain of TGFβRI, which 
triggers the recruitment of intracellular receptor Smad proteins (R-Smad) Smad2 and Smad3, 
leading to their phosphorylation. Phosphorylated Smad2/3 forms a trimeric complex with 
Smad4 and translocates to the nucleus to activate or repress gene expression by binding 
Smad-responsive elements137. Alternatively, TGFβRI can associate with the R-Smads Smad1 
and Smad5. While classically involved in bone morphogenic protein signaling, Smad1/5 can 
be phosphorylated in macrophages to drive alternative gene expression and functional 
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outcomes138,139. In addition to classic Smad-mediated transcription, TGF-β can induce several 
Smad-independent signaling pathways, including MAP kinases, PI3 kinases and Rho 
GTPases140. TGF-β limits its own signaling by promoting transcription of Smad7, which 
blocks binding of R-Smads to TGFβRI or recruits ubiquitin E3 ligases to the receptor, 
degrading TGFβRI141.  
 
Figure 3: Smad-dependent TGF-β signaling.  
 
TGF-β1, 2 and 3 have distinct properties in vivo142, and TGF-β1 is the predominant isoform 
expressed in the immune system137. Tgfb1–/– mice either die in the embryo or after birth by 
multi-organ failure143,144, highlighting a crucial role of this cytokine in controlling innate and 
adaptive immune responses. In the CNS, TGF-β1 has distinct effects on virtually all cell 
types, including microglia. When peripheral expression of TGF-β1 is rescued in Tgfb1–/– 
mice, the resulting CNS-conditional Tgfb1–/– mice do not succumb to multi-organ failure, but 
instead develop neurological deficits which manifest as motor impairments with onset at 4-6 
months135, however the exact mechanism of pathology was not elucidated.  
In the same study, TGF-β1 was shown to be a major regulator of the homeostatic gene 
signature in microglia135. Microglia-specific enhancers are enriched in Smad-binding motifs 
which function in collaboration with the transcription factor PU.1 to drive microglia-specific 
gene expression145. In addition, the transcription factor Sall1, which is unique to microglia, is 
induced by TGF-β118. The importance of TGF-β in defining microglia identity is further 
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underscored by its ability to induce microglia gene expression in vitro, irrespective of 
macrophage type135,145. However, as opposed to alveolar macrophages134 and Langerhans 
cells146-148, microglia do not require TGF-β for development135 or survival in the steady-
state118.  
 
1.10 MICROGLIA AND MONOCYTE FUNCTIONS IN CNS AUTOIMMUNITY  
Experimental autoimmune encephalomyelitis (EAE) is the prototypical model of 
neuroinflammation caused by CNS-infiltrating leukocytes, as evident in multiple sclerosis. 
EAE is induced by immunization with myelin antigens that drive the activation and 
expansion of self-reactive T-cells that subsequently migrate to the CNS. Encephalitogenic T- 
cells alone are capable of driving disease onset, as evidenced by their capacity to adoptively 
transfer disease to the recipient149. Inside the CNS antigenic stimulation by CNS-resident 
phagocytes drives reactivation of self-reactive T-cells. This role is normally assigned to 
DCs150 or leptomeningeal macrophages151 and not microglia152. Infiltrating T-cells produce 
an array of cytokines of which IFN-γ, IL-17 and GM-CSF are probably the most well studied 
examples. Their actions are complex and sometimes opposing, but include increasing the 
permeability of the BBB, activating astrocytes to produce cytokines and licensing phagocytes 
for tissue damage153. These events dramatically alter the immune cell composition in the 
CNS39. Monocytes and monocyte-derived cells are the most prevalent infiltrates at peak of 
disease39, their numbers correlating with disease severity154 and mice that lack circulating 
monocytes are resistant to EAE155-157.  
These studies highlight the non-redundant role of monocytes in initiating and driving tissue 
destruction during EAE. The phagocytic and tissue-destroying capacity of monocytes have 
been linked to the cytokine GM-CSF, since monocyte-specific disruption of the GM-CSF 
receptor protected mice from EAE158. Furthermore, overexpression of GM-CSF in CD4+ T-
cells alone results in myeloid cell infiltration of the CNS and development of fatal 
demyelination159. CNS-resident microglia express low levels of MHCII in the steady state 
and their contribution to EAE severity160 has been attributed to production of inflammatory 
cytokines and reactive oxygen species (ROS)152,161. This is supported by a recent study 
demonstrating that microglia-specific abrogation of the protein kinase TAK1 dramatically 
suppressed EAE by cell-intrinsic downregulation of NFκB signaling162. These studies support 
a detrimental role of microglia during initiation and peak of disease. During the remission 
phase, however, microglia have been proposed to play a beneficial role. Using scanning 
electron microscopy, one study found that while monocytes initiated demyelination at the 
nodes of Ranvier, microglia appeared to scavenge myelin debris163. This is consistent with 
microglia being able to regulate myelination in the steady-state164, during aging165 and 
following demyelinating damage166.   
1.11 MICROGLIA AND MONOCYTE FUNCTIONS IN NEURODEGENERATION 
Neurodegenerative diseases are characterized by the pathological accumulation of misfolded 
and aggregated proteins in the CNS. For a variety of neurodegenerative diseases, specific 
proteins misfold and aggregate in distinct brain regions, working as seeds that can structurally 
corrupt naive proteins167. Neuropathologically, this manifests as a progressive and predictable 
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spreading pattern of aggregates through the brain168. For Alzheimer’s disease the 
neuropathology encompasses extracellular plaques containing amyloid beta protein and 
intracellular neurofibrillary tangles composed of the microtubule-associated protein tau. Both 
amyloid beta and tau aggregates display spreading behavior in Alzheimer’s disease169,170 and 
their aggregation is transmissible171,172. Glial reactions in Alzheimer’s disease have been 
recognized since the original description of the disease173, and microglia are now implicated 
in a number of neurodegenerative disorders11. More recently, microglia have been 
conclusively linked to Alzheimer’s disease by the fact that a majority of the genetic risk loci 
are genes expressed in microglia174. The prevailing hypothesis suggests that microglia 
contribute to Alzheimer’s disease pathology by virtue of their chronic activation and impaired 
clearance mechanisms175. However, complete absence of microglia for 4 weeks did not affect 
amyloid deposition119, and neither did the enforced repopulation of the microglial niche by 
peripherally- derived myeloid cells121,176. Amyloid beta levels were similarly unaffected by 
microglial depletion in the amyloid depositing 5×FAD model, although it prevented neuronal 
loss and improved contextual memory177. The absence of any effect on amyloid beta burden 
by microglia depletion could be explained by recent results suggesting that the key function 
of amyloid-plaque associated microglia, rather than phagocytosis of the amyloid, is to form a 
barrier around it and to compact the amyloid fibrils into a dense plaque178. TREM2, 
haplodeficiency in which increases the risk of Alzheimer’s disease by 4-fold179,180, was found 
to orchestrate this response.  
Research on microglia actions in Alzheimer’s disease has mostly been focused on 
interactions with amyloid beta and not on tau aggregates. This reflects the recognition that 
amyloid beta deposits are extracellular, whereas tau deposits are intraneuronal and not 
normally accessible to microglia. However, activation of microglia in tau transgenic mice 
occurs181-184 and can precede deposition of insoluble tau182. Phagocytosis of tau deposits by 
microglia has been described both in vitro and in vivo185-187. The subsequent release of tau-
containing exosomes has been reported to orchestrate spatiotemporal progression of tau 
pathology via the perforant path185. Interestingly, microglia inflammasome activation has 
been shown to play an analogous role in seeding and spreading of amyloid beta pathology188. 
Reactive microgliosis, as observed in CX3CR1 deficient mice, can drive tau pathology and 
exacerbate cognitive decline189,190. In further support of this notion, peripheral 
lipopolysaccharide administration also significantly exacerbates tau pathology183,191. 
However, to what degree microglia activation occurs in human Alzheimer’s disease brains is 
a matter of debate192. In fact, significant microglial loss is observed in brain areas affected by 
neurofibrillary tangles, and tau oligomers induce microglial apoptosis in vitro193. 
Furthermore, the progression of neurofibrillary pathology is accompanied by the appearance 
of microglia with dystrophic features, including deramification, fragmentation of processes 
and spheroid formation194 which has been interpreted as a sign of cellular senescence195. In 
marmoset brains, which also accumulate fibrillar tau and dystrophic microglia with age, 
hyperphosphorylated tau was only detected in dystrophic but not normal microglia196.  
  
 20 
2 METHODS 
2.1 CRE-FLOX SYSTEM 
The Cre-flox system is a powerful tool which can be used to generate tissue-specific gene 
deletions, turn transgene expression on or off, track individual cells or lineages, report gene 
expression and deplete specific cell types. To achieve cell- or tissue-specific gene deletion, 
mice expressing loxP sites flanking a gene of interest are crossed with mice expressing Cre-
recombinase under a cell-restricted promoter. The Cre-recombinase will then excise the DNA 
inside the loxP-sites. More recently, ligand-dependent chimeric Cre-recombinases (CreER 
recombinases) have been developed which allow Cre-activity to be turned on by the 
administration of tamoxifen197. I have used this system in my studies to delete Tgfbr2 in 
distinct cell subsets (see GENE TARGETING) and to specifically deplete microglia. 
 
2.2 MICROGLIA DEPLETION 
Depletion of microglia has been widely used to address their role in different 
neuropathological contexts112. One of the main goals of my thesis work has been to produce a 
model system in which depletion of microglia could be accomplished with high efficiency 
and for longer periods of time, in order to study microglial functions in different 
neuroinflammatory and neurodegenerative settings.  
Studying macrophage functions in vivo by their conditional depletion has a long history. 
Early experiments employed silica and asbestos to deplete macrophages198. The depletion 
technique became mainstream following the development of clodronate-encapsulated 
liposomes199, which are still frequently used today. During the past decade this technique has 
been superseded by mice expressing the diphtheria toxin receptor (DTR) specifically in the 
cell type of interest200. Depletion can then be accomplished by administration of diphtheria 
toxin (DT).  
We first used transgenic mice expressing DTR under the CD11b promoter (CD11b-DTR 
mice201) and administered DT intraperitoneally at doses that had previously been used to 
deplete peripheral macrophage populations, but failed to detect any signs of microglia 
depletion (Figure 4A). A study published at the same time accomplished only transient 
depletion (recovered in 36 hours) of microglia using peripheral administration of DT in 
CD11b-DTR mice42. We thus attempted to administer DT directly to the brain, which 
counterintuitively resulted in significantly increased numbers of microglia (Figure 4B). 
Continuous delivery of DT for 14 days using an intracerebroventricular cannula was equally 
ineffective (Figure 4C), despite having been reported to be efficient using gangciclovir in 
CD11b-HSVTK mice119.  
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Figure 4: Attempted microglial depletion using CD11b-DTR mice and administration of DT by various routes; 
(A) two intraperitoneal doses (B) one intracerebroventricular dose or (C) 14 day continuous 
intracerebroventricular delivery through a cannula connected to an osmotic pump.  
 
The development of Cx3cr1CreER mice by two independent laboratories47,162 permitted 
specific depletion of microglia when crossed with R26DTR mice, which have the DTR inserted 
into the ubiquitously expressed Rosa26 locus200. Widespread expression of DTR is blocked 
by an upstream loxP-flanked STOP cassette. Tamoxifen administration in 
Cx3cr1CreER/+R26DTR/+ thus results in excision of the stop cassette, allowing transcription of 
DTR in microglia. DT administration in these mice initially appeared promising to us as we 
achieved approximately 80% depletion (Figure 5A). However, as later published116, rapid 
microglial proliferation quickly compensated the cellular loss (Figure 5A). Additional cycles 
of TAM and DT could not meaningfully reduce the microglial pool (Figure 5A). To 
circumvent the need for DT to reach the brain, we crossed Cx3cr1CreER mice with R26DTA 
mice202, in which tamoxifen administration resulted in almost complete eradication of 
microglia (Figure 5B). However, macrophage populations possess an inherent resistance 
against depletion and the microglial population could rebound even after >99% depletion 
(Figure 5B). As detailed in Paper II, the microglial niche was repopulated by a combined 
process of CNS-resident proliferation and infiltration of Ly6Chi monocytes, generating 
F4/80low and F4/80hi cells, respectively. This model is useful to study the impact of microglia 
with short time frames (>90% depleted from day 2-10), as well as mechanisms of 
repopulation (Paper II).  
To study microglial functions during longer time frames, as is relevant in neurodegenerative 
disease models, we continuously administered tamoxifen to Cx3cr1CreER/+R26DTA/+ mice over 
the course of one month. Repeated subcutaneous administration or continuous administration 
in the chow resulted in depletion efficiencies of 60-70% (Figure 5C-D) and this protocol was 
used in Paper IV.  
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Figure 5: Depletion/repopulation kinetics in (A) Cx3cr1CreERR26DTR mice receiving one, two or three cycles of 
tamoxifen and DT or (B-D) Cx3cr1CreERR26DTA mice receiving (B) three subcutaneous doses of tamoxifen (C) 
repeated subcutaneous tamoxifen injections or (D) continuous delivery of tamoxifen in the chow.  
 
2.3 GENE TARGETING 
Deletion of Tgfbr2 in specific monocyte/macrophage subsets was achieved by crossing 
Tgfbr2fl/fl (floxed) mice203 with LysMCre mice204 or Cx3cr1CreER mice 47. LysMCre mice 
efficiently deleted Tgfbr2 in monocytes (Paper III) and monocyte-derived macrophages 
during EAE (Paper I), but not microglia (Paper I). Cx3cr1CreER mice were used to target 
microglia (Paper III). Due to upregulation of CX3CR1 mRNA and protein during microglia 
niche colonization, monocyte-derived macrophages could be targeted using 
Cx3cr1CreER/+Tgfbr2fl/fl→Cx3cr1CreER/+R26DTA/+ chimeras.  
 
2.4 MICROGLIA, MONOCYTE AND MACROPHAGE NOMENCLATURE 
In this thesis I present studies related to microglia, monocytes and monocyte-derived cells 
and the nomenclature used can be both complicated and easily confused. The following 
  23 
section aims to clarify the nomenclature and strategies employed to separate these 
populations.  
Separation of microglia from infiltrating macrophages during neuroinflammatory conditions 
is complicated, if not impossible, using traditional techniques such as immunohistochemistry. 
The introduction of multi-color flow cytometry and production of reliable fluorophore-
conjugated antibody clones have significantly simplified this task. More recently, the use of 
unsupervised high-dimensional cytometry has permitted excellent separation of the myeloid 
compartment in a range of tissues205,206, including the CNS during both steady-state and 
neuroinflammatory conditions39,207,208. In our studies we have used a panel of up to eight 
markers for flow cytometry that has allowed us to adequately delineate the CNS myeloid 
compartment. In the naive brain, microglia dominate the myeloid compartment and are easily 
separated from blood-derived leukocytes based on their lower expression of CD45. During 
EAE, microglia become activated and alter their surface marker expression39 yet remain 
distinguishable209 as CD45low. Simultaneously, a heterogeneous population of myeloid cells 
infiltrates the CNS, including but not limited to neutrophils, monocytes and conventional 
DCs. Ly6G expression readily distinguishes neutrophils. Monocytes give rise to 
inflammatory ‘monocyte-derived’ cells that are characterized as MHCIIhiLy6C+CD11c+. 
They are the most abundant leukocytes infiltrating the parenchyma during EAE153, but their 
nomenclature can be confusing. Some studies refer to them as inflammatory monocyte-
derived macrophages or simply macrophages whereas the term monocyte-derived dendritic 
cells (moDC) is also widely used. This latter term can easily lead to confusion with 
conventional DCs, which make only a limited contribution to the CNS myeloid pool during 
EAE39,209, and can be separated from the monocyte-derived pool based on F4/80 expression. 
In Paper I we have employed the term moDC for consistency with previous studies.  
In Paper II we describe CX3CR1+F4/80hi macrophages that arise from brain-infiltrating 
monocytes following microglial depletion. While these macrophages adopt a surface 
phenotype (MHCIIlowF4/80hiCD11clowLy6C–) that is distinct from inflammatory moDCs, 
they also derive from the circulating Ly6Chi monocyte pool.  
Non-parenchymal border-associated (meningeal, perivascular, choroid plexus) macrophages 
can comprise up to 10% of the CNS myeloid compartment during steady-state, do not expand 
during EAE but are difficult to separate from microglia and monocyte-derived cells using 
conventional flow cytometry markers38,39. We have not actively separated these cells from 
microglia or infiltrating leukocytes in our studies. 
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3 RESULTS AND DISCUSSION 
 
3.1 PAPER I: TGF-β SIGNALING IN MONOCYTE-DERIVED CELLS INITIATES 
EAE REMISSION  
Previous work in our research group described immunomodulatory effects of TGF-β on 
macrophages and microglia in vitro and when transferred into autoimmune disease models of 
type 1 diabetes210 and multiple sclerosis211. In addition, work by other groups had 
demonstrated beneficial effects of phagocyte-specific abrogation of TGF-β signaling in 
settings of bacterial meningitis212 and tumor growth213,214. This indicated that the immune-
dampening effects of TGF-β on the myeloid compartment were deleterious during settings of 
cancer and infection, but beneficial during autoimmunity. Furthermore, while potent effects 
of administering or inhibiting TGF-β on the course of EAE had been described215-218 the 
cellular targets of these therapies were not well defined. We knew that the spinal cord 
macrophage load correlated with disease severity154,157 and that TGF-β production and 
signaling was at its strongest at the peak of EAE218-220.  
We thus hypothesized that TGF-β signaling in myeloid cells would regulate autoimmune 
neuroinflammation. Specifically, we thought that during the course of the inflammatory 
response TGF-β could work as a switch to control macrophage-induced spinal cord damage. 
To address this hypothesis, we crossed LysMCre and Tgfbr2fl/fl mice to specifically target 
TGF-β signaling in myeloid cells. Importantly, we did not detect spontaneous alterations in 
the immune compartments of the spleen or lymph nodes during steady state. Our lack of 
peripheral immune activation convinced us that we were not affecting TGF-β signaling in 
conventional DCs, an event which had been described to result in increased T-cell activation 
and spontaneous autoimmunity221,222. After immunization with myelin oligodendrocyte 
glycoprotein we observed no differences in the onset of disease, suggesting that T-cell 
priming and re-activation in the CNS were not affected. At peak of disease we observed no 
differences in cellular infiltrates or production of IL-17 or IFN-γ by T-cells retrieved from the 
CNS. Differences in the EAE score were apparent from day 16; LysMCre/+Tgfbr2fl/fl mice did 
not enter remission, which normally occurs in WT mice. In fact we did not detect any 
improvement of EAE symptoms in LysMCre/+Tgfbr2fl/fl mice throughout the study period (30 
days). This chronic EAE stage was characterized by a selective retention of Tgfbr2–/– and 
MHCIIhi moDCs in the spinal cord and a concomitant switch in T-cell cytokine profile 
favoring IFN-γ production.  
Subsequent sets of experiments provided a mechanism for the perpetuation of disease by 
demonstrating that: i) TGF-β could directly limit inflammation-induced IL-12, but not IL-23 
production in macrophages, which (ii) could directly shift T-cell toward IFN-γ production. 
iii) Tgfbr2–/– moDCs were characterized by increased Nox2 expression and ROS-production. 
iv) ROS-production in macrophages was TGF-β and IFN-γ dependent. This mechanism is 
illustrated in Figure 6. Taken together our data demonstrated that TGF-β signaling controlled 
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activation of moDCs in the spinal cord, which is crucial for the initiation of EAE remission. It 
also provides a (TGF-β dependent) mechanism for the observation that the monocyte-
compartment contracts during EAE remission154. 
 
 
Figure 6: Suggested mechanism whereby TGF-β regulates chronic EAE 
 
3.2 PAPER II: REPOPULATION OF THE MICROGLIAL NICHE BY MONOCYTE-
DERIVED MACROPHAGES 
In Paper I we addressed the role of TGF-β signaling in monocyte-derived cells during T-cell 
initiated neuroinflammatory disease. In the subsequent papers we developed the tools 
necessary (Paper II) to address the function of TGF-β (Paper III) in microglia and 
monocyte-derived macrophages during steady-state conditions.  
In Paper II we provided a new model of microglia depletion by crossing Cx3cr1CreER and 
R26DTA mice and administered tamoxifen to the offspring, resulting in >95 % depletion of 
microglia. Subsequently, we observed that microglia were repopulated by a combined 
mechanism of intrinsic proliferation of surviving microglia and infiltration of monocytes. It 
should be noted that these two processes have been reported separately and are not novel per 
se28,116,120. However, repopulation by peripherally-derived myeloid cells was previously 
described to occur only under conditions in which the BBB is damaged, and is considered by 
many to be an experimental artifact223. In light of the results presented in Paper II as well as 
recently published data, I believe this concept needs revision. Below I discuss the factors 
regulating peripheral repopulation taking into account current and previous models of 
microglia depletion.  
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BBB disruption: Cx3cr1CreERR26DTR mice are repopulated by peripheral myeloid cells only 
after whole-body irradiation116, which led authors to suggest that this was a prerequisite for 
repopulation. Furthermore, the peripheral repopulation observed by Varvel et al. in CD11b-
HSVTK mice120 required an intracerebroventricular cannula, and damage to the BBB can 
thus not be excluded. However, this conclusion was always speculative and not based on firm 
experimental data. As we observed in Paper II, BBB disruption did not occur after microglia 
depletion in Cx3cr1CreERR26DTA mice. Lack of BBB disruption was confirmed by a recent 
paper from Cronk et al. using Cx3cr1CreERCsf1rfl/fl mice to partially deplete microglia for up 
to 12 weeks, resulting in repopulation by monocyte-derived cells224. 
Stem cells in the circulation: Since peripheral repopulation was enhanced under settings of 
irradiation and bone-marrow transplantation, where stem and progenitors cells are released 
into the circulation en masse, it has been suggested that peripheral ‘microglia’ arose from 
myeloid progenitors without passing through a monocyte intermediate116,154. Furthermore 
Bruttger et al. observed that a monocyte-depleting antibody did not impair peripheral 
repopulation in whole-body irradiated Cx3cr1CreERR26DTR mice116. However, we could 
reconstitute the microglial niche of Cx3cr1CreERR26DTA mice through adoptive transfer of 
purified Ly6Chi monocytes. This was confirmed in Cx3cr1CreERCsf1rfl/fl mice by Cronk et al. 
who additionally used parabiosis to conclusively show that monocytes can replace microglia 
under physiological conditions224.  
Brain inflammation: Does microglial death induce an inflammatory reaction in the brain that 
is sufficient to cause peripheral myeloid cells to engraft? We did observe a strong 
inflammatory response in the brain of Cx3cr1CreERR26DTA mice following depletion, as 
evidenced by astrocyte activation and cytokine production, although this had largely 
dissipated within two weeks. Importantly, however, Bruttger et al. also reported astrocytosis 
and production of pro-inflammatory cytokines in the brains of Cx3cr1CreERR26DTR mice 
whereby approximately 80% of microglia were depleted but no peripheral repopulation was 
observed116. Thus, 80% microglia death is not sufficient to cause any peripheral repopulation, 
yet as demonstrated by Cronk et al., 25% sustained depletion is. Inflammation caused by 
primary microglia death alone is therefore unlikely to account for peripheral repopulation.  
Microglia loss of proliferative activity: Our results support a model whereby impaired 
microglial proliferative capacity is an important factor regulating peripheral repopulation. 
Despite active proliferation following depletion in Cx3cr1CreERR26DTA mice, microglia do not 
recover the entire niche. By contrast, Cx3cr1CreERR26DTR mice recover their microglial loss in 
a matter of days through hyperproliferation of the surviving microglia116, which could explain 
why monocytes are not given an advantage. This is further supported by the peripheral 
repopulation observed following chronic tamoxifen treatment in Cx3cr1CreERCsf1rfl/fl mice224, 
which likely results in permanent impairment of microglial proliferative capacity. This is of 
course contradicted by the observation that microglia can be virtually eradicated using a 
CSF1R antagonist and that when drug administration is ceased the few surviving microglia 
repopulate the niche without peripheral help28,117. However, in those experiments the chronic 
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inhibition of CSF1R likely simultaneously impairs monocytes from colonizing the niche. 
Furthermore, why monocytes are given an advantage over microglia following depletion in 
CD11b-HSVTK mice120,121 remains to be elucidated.  
Taken together, none of these factors alone can explain why monocytes repopulate the 
microglial niche. It is possible that a combination of these factors can synergize at a 
microcompartmental level not evident when the CNS is analyzed in bulk. Importantly, the 
conclusion from the studies mentioned above is that peripheral repopulation by the microglial 
niche can occur even under physiological conditions. As discussed in the Introduction there 
are certain conditions, such as infection or injury, that can lead to permanent replacement of 
alveolar macrophage or Kupffer cell pools with monocyte-derived macrophages. It would 
thus be of great interest to investigate whether survivable CNS infections or trauma would 
result in long-term integration of monocyte-derived macrophages into the parenchyma. 
Considering that humans live for many decades and may experience one or several CNS 
insults (i.e. concussion, stroke) throughout life, it is not inconceivable that the human 
microglial pool becomes diluted with monocyte-derived macrophages.  
Another interesting aspect of our study is the identification of markers that can specifically 
distinguish monocyte-derived macrophages from microglia. Transcriptional profiling 
identified several candidates, including Clec12a and CXCR4, which were also upregulated at 
the protein level. In future studies, it would be interesting to apply these markers in various 
murine disease models or human brain samples where such discrimination is difficult. Of 
note, several genes of the Ms4a cluster on mouse chromosome 19 were among the most 
highly upregulated in monocyte-derived macrophages. Variants in MS4A genes have been 
identified in genome-wide association studies and are associated with risk of developing 
Alzheimer’s disease, but the mechanism remains obscure225. Another interesting observation 
in this regard is the high overlap of our peripherally-derived macrophage gene signature with 
the one observed in microglia from Sall1 deficient mice118. Consistently, Sall1 and its 
homolog Sall3, which are microglia-specific transcription factors, were among the most 
significantly downregulated genes in monocyte-derived macrophages in our gene set. This 
indicates that monocytes utilize alternative transcription factors to obtain ‘microglia-like’ 
phenotype and function.  
In conclusion, there are a number of outstanding questions that would be of great interest to 
investigate. In light of recently identified subsets of monocytes80,81, is there a specific subset 
of Ly6Chi monocytes that replaces microglia? Furthermore, type I and II interferon-signaling 
was highly enriched in peripherally derived microglia, therefore how do interferons regulate 
replacement of microglia by monocytes? Finally, given the recent observation that microglia 
have an epigenetic ‘memory’ of previous inflammatory stimuli226, do monocyte-derived 
macrophages that repopulate the microglial niche contain an epigenetic record of experiences 
in the bone marrow or blood?  
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3.3 PAPER III: TGF-β REGULATES FUNCTIONAL COLONIZATION OF THE 
MICROGLIAL NICHE 
Our results in Paper II demonstrated that monocytes could integrate long-term into the 
microglial niche and adopt microglia-gene expression and function. An obvious follow-up 
question was whether response to microglia niche factors was required for this integration. In 
the years leading up to the conception of this study, several articles were published which 
described the specific gene signature of microglia using microarray or RNA-seq 
technologies227. Subsequently, TGF-β was identified as as a key signal in the development 
and maintenance of this gene signature in microglia135,228. We thus hypothesized that TGF-
β signaling in monocytes was required for microglial niche colonization. We thus 
produced LysMCre/+Tgfbr2fl/fl →Cx3cr1CreER/+R26DTA/+ chimeric mice, depleted microglia and 
sorted the newly repopulating macrophages. This demonstrated that monocytes lacking TGF-
β signaling did not colonize the microglial niche which could reflect a requirement of TGF-β 
for CNS entry. Consistent with this, TGF-β can induce chemotaxis229,230 and upregulate 
surface integrin expression231 on human monocytes. However, this idea is strongly 
contradicted by our observations in Paper I, where Tgfbr2 deficient monocytes were not 
impaired from entering the CNS during EAE. I would instead argue that under the 
circumstances present during microglial depletion, differentiation into CX3CR1+ ‘microglia-
like’ cells requires active TGF-β signaling in monocytes. This further highlights that the 
process generating macrophages under neuroinflammatory conditions (Paper I) may be 
significantly different from that generating macrophages to replace microglia (Paper III). It 
could also indicate that these two macrophage populations are generated by different subsets 
of monocytes that are differentially dependent on TGF-β and should be further addressed.  
Strikingly, when we instead abrogated TGF-β signaling in macrophages after colonization of 
the niche (using Cx3cr1CreER/+Tgfbr2fl/fl→Cx3cr1CreER/+R26DTA/+ chimeras), mice developed a 
progressive and fatal motor disease. Subsequent experiments demonstrated that macrophages 
were transcriptionally reprogrammed by the loss of Tgfbr2 and spontaneously enacted 
demyelination in the spinal cord. Furthermore, using Cx3cr1CreER/+Tgfbr2fl mice we also 
demonstrated that microglia lacking TGF-β signaling developed a similar motor disease but 
with significantly slower pace. These mechanisms are depicted in Figure 7.  
Our results provide a pathological mechanism for the observation by Butovsky et al. that 
Tgfb1 deficient mice develop motor disease at 4-6 months of age135. No CNS lesions were 
described in that study, which made it difficult to dissect the loss of TGF-β signaling on 
individual immune cell subsets or even neurons or astrocytes. In addition, motor symptoms in 
CNS-Tgfb1–/– mice were accompanied by the appearance of Ly6Chi cells in the CNS, which 
made it difficult to assign the pathology to resident or infiltrating subsets135. 
The relevance of the TGF-β pathway to neurological disease is further underscored by the 
recent observation that TGF-β signaling is suppressed in several neurodegenerative disease 
models, including Alzheimer’s disease232. In that study neurodegenerative microglia were 
instead characterized by activation of pathways induced by TREM2 and APOE, genetic 
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variants in which significantly increase the risk of developing Alzheimer’s disease233. 
Furthermore, a meta-study determined TGF-β1 to be the only cytokine upregulated in the 
cerebrospinal fluid of Alzheimer’s disease patients234, indicating that TGF-β signaling is 
dysregulated in this disease. 
  
Figure 7: Mechanism whereby TGF-β regulates the integration of monocytes into empty microglial niches. 
Maintenance of the homeostatic microglia gene signature requires TGF-β (top left box). Colonization of 
microglial niches requires TGF-β signaling in monocytes. After integration into the niche TGF-β is required for 
homeostatic functions in monocyte-derived macrophages (bottom left box). In the absence of TGF-β signaling, 
monocyte-derived macrophages become licensed for tissue damage, attack axons and become giant myelin-filled 
cells (right box).  
 
One observation that requires further investigation was the fact that chimeric 
Cx3cr1CreER/+Tgfbr2fl/fl→Cx3cr1CreER/+R26DTA/+ mice consistently developed lesions in the 
same anatomical areas. This was most predominant in the dorsal column of the spinal cord 
which was consistently degenerated at the end stage of disease, whereas the ventral columns 
were always untouched. Similarly, lesions in the thalamus were observed in all end-stage 
mice, but other areas of the cerebrum appeared normal. Microglia are known to display 
region-dependent gene expression235, and our results thus suggest the existence of sub-
compartment specific vulnerability to loss of TGF-β signaling. 
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3.4 PAPER IV: MICROGLIA REGULATION OF ALZHEIMER’S DISEASE TAU 
PATHOLOGY 
In Paper IV we addressed the long-term consequences of microglial loss on tau pathology. 
Almost all transgenic mouse models of neurodegenerative disease share the common feature 
that the neuropathology is paralleled by robust microgliosis. This is also true for mouse 
models of tauopathy expressing the frontotemporal dementia-associated mutants P301S and 
P301L. In this study we used a mouse model (hTau mice) in which pathology is significantly 
less aggressive. Levels of insoluble tau are lower than in P301L mice236 and neuronal loss 
develops only at an advanced age (15 months)237. Nevertheless, hTau mice develop 
hippocampal-dependent spatial memory deficits by 7-12 months of age190,238,239. In this study 
we first characterized the microglial phenotype and were surprised to discover an apparent 
lack of microglial activation, cytokine production and proliferation. Even at an advanced age 
(22 months) we did not detect altered gene expression in microglia as a consequence of tau 
pathology. hTau mice thus represent a mouse model in which microglial activation does not 
visibly contribute to disease progression. This is in contrast to most transgenic mouse models 
of proteinopathic neurodegenerative diseases, in which microglial depletion almost invariably 
leads to improvement of neuropathology, as we have previously reviewed112. In this context, 
we thus hypothesized that microglial depletion in hTau mice would lead to an 
exacerbation of disease. However, to our surprise we did not detect any impact on tau 
aggregation and associated spatial memory impairment as a consequence of chronic 
microglial depletion.  
It is possible that the limited degree of depletion and the relatively mild pathology observed 
in hTau mice was not enough to yield robust differences in clinical and biochemical readouts. 
Indeed, hTau mice present with several-fold lower insoluble tau compared to P301L 
transgenic mice236. However, it could be argued that the extended depletion time used (3 
months) in this study should compensate for the incomplete depletion. Additional 
experiments in older hTau mice with more robust pathology as well as using the CSF1R 
inhibitor that can produce >99% long-term depletion would address these concerns.  
In summary, despite the lack of effect on tau pathology, the model presented in this 
manuscript represents a novel and useful tool to address microglial functions in 
neuropathological contexts.  
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4 FUTURE PERSPECTIVES 
The past decade has produced a formidable body of literature placing microglia at the center 
stage of development, homeostasis and aging of the brain. Based on the results presented in 
this thesis, I propose three questions that should guide future research.  
To what extent are peripherally-derived macrophages observed in the human brain? 
While this question has been pondered for many years, our studies and those of others have 
now identified markers that should be further explored in developing reagents that can 
specifically label central vs peripheral ‘microglia’. Such studies are already underway240.  
What are the tissue specific cues that regulate microglia disease states? Microglia 
activation states were for a long time oversimplified, characterized as a dichotomy of ‘good’ 
and ‘bad’ based on only a limited set of markers241. New studies have demonstrated that 
macrophages have complex states that are often guided by tissue-specific cues. Each tissue-
resident macrophage population is probably guided by a collection of distinct cues that 
creates tissue-specific contexts. As our study shows, identification of these tissue-specific 
contexts is vital for understanding disease.  
Which pathways in microglia drive neurodegeneration and can be pharmacologically 
targeted? A growing number of studies have reported neurological deficits similar to those 
identified in our study, as a direct consequence of dysregulation of signaling pathways in 
CNS macrophages. This includes mice with overexpression of GM-CSF159, deficiency in 
NRROS242, mutations in BRAF243 or constitutive activation of NF-κB244. This indicates that 
several pathways could converge to create ‘common’ neurodegenerative signatures in 
microglia and some candidates have already been proposed232,245. Targeting these pathways 
pharmacologically may represent avenues for therapy.  
  
 32 
5 ACKNOWLEDGEMENTS 
I would like to start by thanking my uncle Ron and my aunt Lalla for inspiring me to commit 
to a career in science.  
I am very grateful to my main supervisor and good friend Bob for his constant motivation 
and selfless support of my ideas and ambitions. For going out of his way to bring financial 
support to the projects and to promote the work that I do. I want to thank my co-supervisor 
and friend Xingmei for transferring at least some of her tremendous technical know-how. For 
her amazing sense of humor and positive outlook on life. I am extremely grateful to have 
worked with Roham, whose strife to do good science is a constant source of inspiration. 
Thank you for taking the lab to the next level, for always asking the challenging questions, 
and for being a good friend. I am very glad to have had the opportunity to work with Melanie 
who has such an inspirational work ethic and a very impressive technical register. This thesis 
work would not have been possible without the endless hours she has put in. I am grateful to 
Keying and Jinming for participating in my projects with such interest and technical 
expertise. I would like to thank the most scientifically astute master student I have met, 
David, for all his hard work. Sohel, thank you for your wisdom, inspiring ambition and good 
company. I am grateful to have earned the close friendship of Rasmus, Karl, Petra and 
André. Thank you for all the wonderful travels, your passion for science and for making it a 
pleasure to come to work. Thanks to Mohsen for keeping the lab in such good shape and for 
always helping out. I am grateful to my co-supervisor Tomas Olsson for creating an open 
and creative atmosphere in the lab and for providing support to projects. I appreciate the help 
and critical input on project ideas of my co-supervisor Richard Cowburn.  
I would like to thank Maja Jagodic and members of her group for valuable input and help 
with projects: I am particularly grateful to Ewoud for enduring my requests to analyze and 
reanalyze sequencing data and for his attempts to help me understand it. Thank you Lara, 
Sabrina and Maria for your continuing commitment to my project. I would like to thank 
Fredrik Piehl for valuable scientific input. I am very grateful for all the project input, 
interesting scientific discussions and life discussions to present and past members of the PhD 
room: Marie, Eliane, Sabrina, Andreas, Sevi, Hannes, Mathias, Melanie. Other people to 
whom I am grateful for their input and company: Alex, Rux, Sreeni, Nånnis, Nada, Maria, 
Susi, Ramil and Venus.  
I am forever grateful to my mentors and close friends Anne and Dan at Offspring 
Biosciences for training me in histology and for their never-ending generosity and 
helpfulness with all things histology-related. I would also like to thank Anders and Mia for 
all their help and input.  
Thank you to the animal house staff at AKM for taking care of our mice all these years, 
especially Elisabeth Qvist, Freja Engström and Sandra Olsson. I am very grateful to 
Michelle Gustafsson for performing perfect iv injections. I would like to acknowledge the 
skillful and committed cell sorting work by Annika van Vollenhoven.  
I appreciate the interesting collaboration with the human genetics group, thank you Ingrid, 
Sandra and Tojo. I would like to acknowledge Tobias Suter and his colleagues for a 
productive collaboration on the Glia paper. I would like to express my appreciation to Oleg 
  33 
Butovsky for sharing antibodies and giving valuable input on our projects. I am very thankful 
to Eva Hedlund and Jik Nijssen for performing neuromuscular junction analysis and 
discussing the data for the Nature Immunology paper. I would also like to thank Daniel 
Ketelhuth and Maria Forteza for productive collaboration on metabolism related to this 
study. I am grateful to Klas Blomgren and Makiko Ohshima for planning and performing 
behavioral analyses on hTau mice and for sharing mice. I appreciated the fruitful 
collaboration on amyloid beta transfer with Martin Hallbeck, Valerie Sackmann and Anna 
Ansell. Thanks to Fredrik Wermeling for project input and generosity with mice.  
Special thanks to Ylva Petersdotter for making the beautiful cover of this thesis.  
I would like to thank my mother and father and my brother and sister for staying interested 
in what I do throughout all the years. Lastly I would like to thank my family Mina, Otto and 
Folke for putting up with all the late nights, the working weekends and the obsession with 
science.       
 
  
 34 
6 REFERENCES 
 
1. Hulsmans, M. et al. Macrophages Facilitate Electrical Conduction in the Heart. Cell 169, 510–
522.e20 (2017). 
2. Collin, M. & Milne, P. Langerhans cell origin and regulation. Curr. Opin. Hematol. 23, 28–35 
(2016). 
3. Sierra, A. et al. The ‘Big-Bang’ for modern glial biology: Translation and comments on Pío del 
Río-Hortega 1919 series of papers on microglia. Glia 64, 1801–1840 (2016). 
4. Sródka, A., Gryglewski, R. W. & Szczepariski, W. Browicz or Kupffer cells? Pol J Pathol 57, 183–
185 (2006). 
5. Geissmann, F., Jung, S. & Littman, D. R. Blood monocytes consist of two principal subsets with 
distinct migratory properties. Immunity 19, 71–82 (2003). 
6. Auffray, C. et al. Monitoring of blood vessels and tissues by a population of monocytes with 
patrolling behavior. Science 317, 666–670 (2007). 
7. Carlin, L. M. et al. Nr4a1-Dependent Ly6Clow Monocytes Monitor Endothelial Cells and 
Orchestrate Their Disposal. Cell 153, 362–375 (2013). 
8. Zaidi, M. et al. Osteoclast function and its control. Exp. Physiol. 78, 721–739 (1993). 
9. van Furth, R. et al. The mononuclear phagocyte system: a new classification of macrophages, 
monocytes, and their precursor cells. Bull. World Health Organ. 46, 845–852 (1972). 
10. Ginhoux, F. & Guilliams, M. Tissue-Resident Macrophage Ontogeny and Homeostasis. Immunity 
44, 439–449 (2016). 
11. Li, Q. & Barres, B. A. Microglia and macrophages in brain homeostasis and disease. Nat. Rev. 
Immunol 123, 229 (2017). 
12. Hoeffel, G. et al. C-Myb+ Erythro-Myeloid Progenitor-Derived Fetal Monocytes Give Rise to 
Adult Tissue-Resident Macrophages. Immunity 42, 665–678 (2015). 
13. Sheng, J., Ruedl, C. & Karjalainen, K. Most Tissue-Resident Macrophages Except Microglia Are 
Derived from Fetal Hematopoietic Stem Cells. Immunity 43, 382–393 (2015). 
14. Gomez Perdiguero, E. et al. Tissue-resident macrophages originate from yolk-sac-derived erythro-
myeloid progenitors. Nature 518, 547–551 (2015). 
15. Ginhoux, F., Lim, S., Hoeffel, G., Low, D. & Huber, T. Origin and differentiation of microglia. 
Front. Cell. Neurosci. 7, 45 (2013). 
16. Guilliams, M. & Scott, C. L. Does niche competition determine the origin of tissue-resident 
macrophages? Nat. Rev. Immunol 17, 451–460 (2017). 
17. Bonnardel, J. & Guilliams, M. Developmental control of macrophage function. Current Opinion in 
Immunology 50, 64–74 (2018). 
18. Río-Hortega, P. The Microglia. Lancet 233, 1023–1026 (1939). 
19. Alliot, F., Godin, I. & Pessac, B. Microglia derive from progenitors, originating from the yolk sac, 
and which proliferate in the brain. Brain Res. Dev. Brain Res. 117, 145–152 (1999). 
20. Ginhoux, F. et al. Fate Mapping Analysis Reveals That Adult Microglia Derive from Primitive 
Macrophages. Science 330, 841–845 (2010). 
21. Kierdorf, K. et al. Microglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent 
pathways. Nat. Neurosci. 16, 273–280 (2013). 
22. McKercher, S. R. et al. Targeted disruption of the PU.1 gene results in multiple hematopoietic 
abnormalities. EMBO J. 15, 5647–5658 (1996). 
23. Matcovitch-Natan, O. et al. Microglia development follows a stepwise program to regulate brain 
homeostasis. Science 353, aad8670–aad8670 (2016). 
24. Thion, M. S. et al. Microbiome Influences Prenatal and Adult Microglia in a Sex-Specific Manner. 
Cell 172, 500–516.e16 (2018). 
25. Erny, D. et al. Host microbiota constantly control maturation and function of microglia in the CNS. 
Nat. Neurosci. 18, 965–977 (2015). 
26. Ajami, B., Bennett, J. L., Krieger, C., Tetzlaff, W. & Rossi, F. M. V. Local self-renewal can sustain 
CNS microglia maintenance and function throughout adult life. Nat. Neurosci. 10, 1538–1543 
(2007). 
27. Hashimoto, D. et al. Tissue-Resident Macrophages Self-Maintain Locally throughout Adult Life 
with Minimal Contribution from Circulating Monocytes. Immunity 38, 792–804 (2013). 
28. Elmore, M. R. P. et al. Colony-Stimulating Factor 1 Receptor Signaling Is Necessary for Microglia 
Viability, Unmasking a Microglia Progenitor Cell in the Adult Brain. Neuron 82, 380–397 (2014). 
29. Greter, M. et al. GM-CSF Controls Nonlymphoid Tissue Dendritic Cell Homeostasis but Is 
Dispensable for the Differentiation of Inflammatory Dendritic Cells. Immunity 36, 1031–1046 
(2012). 
  35 
30. Wang, Y. et al. IL-34 is a tissue-restricted ligand of CSF1R required for the development of 
Langerhans cells and microglia. Nat Immunol 13, 753–760 (2012). 
31. Askew, K. et al. Coupled Proliferation and Apoptosis Maintain the Rapid Turnover of Microglia in 
the Adult Brain. Cell Reports 18, 391–405 (2017). 
32. Tay, T. L. et al. A new fate mapping system reveals context-dependent random or clonal expansion 
of microglia. Nat. Neurosci. 20, 793–803 (2017). 
33. Füger, P. et al. Microglia turnover with aging and in an Alzheimer's model via long-term in vivo 
single-cell imaging. Nat. Neurosci. 20, 1371–1376 (2017). 
34. Réu, P. et al. The Lifespan and Turnover of Microglia in the Human Brain. Cell Reports 20, 779–
784 (2017). 
35. Prinz, M., Erny, D. & Hagemeyer, N. Ontogeny and homeostasis of CNS myeloid cells. Nat 
Immunol 18, 385–392 (2017). 
36. Hickey, W. F. & Kimura, H. Perivascular microglial cells of the CNS are bone marrow-derived and 
present antigen in vivo. Science 239, 290–292 (1988). 
37. Mildner, A. et al. Microglia in the adult brain arise from Ly-6ChiCCR2+ monocytes only under 
defined host conditions. Nat. Neurosci. 10, 1544–1553 (2007). 
38. Goldmann, T. et al. Origin, fate and dynamics of macrophages at central nervous system interfaces. 
Nat Immunol 17, 797–805 (2016). 
39. Mrdjen, D. et al. High-Dimensional Single-Cell Mapping of Central Nervous System Immune Cells 
Reveals Distinct Myeloid Subsets in Health, Aging, and Disease. Immunity 48, 380–395.e6 (2018). 
40. Wakselman, S. et al. Developmental neuronal death in hippocampus requires the microglial CD11b 
integrin and DAP12 immunoreceptor. J. Neurosci. 28, 8138–8143 (2008). 
41. Marín-Teva, J. L. et al. Microglia promote the death of developing Purkinje cells. Neuron 41, 535–
547 (2004). 
42. Ueno, M. et al. Layer V cortical neurons require microglial support for survival during postnatal 
development. Nat. Neurosci. 16, 543–551 (2013). 
43. Squarzoni, P. et al. Microglia Modulate Wiring of the Embryonic Forebrain. Cell Reports 8, 1271–
1279 (2014). 
44. Paolicelli, R. C. et al. Synaptic pruning by microglia is necessary for normal brain development. 
Science 333, 1456–1458 (2011). 
45. Stevens, B. et al. The classical complement cascade mediates CNS synapse elimination. Cell 131, 
1164–1178 (2007). 
46. Schafer, D. P. et al. Microglia sculpt postnatal neural circuits in an activity and complement-
dependent manner. Neuron 74, 691–705 (2012). 
47. Parkhurst, C. N. et al. Microglia Promote Learning-Dependent Synapse Formation through Brain-
Derived Neurotrophic Factor. Cell 155, 1596–1609 (2013). 
48. Presumey, J., Bialas, A. R. & Carroll, M. C. Complement System in Neural Synapse Elimination in 
Development and Disease. Adv. Immunol. 135, 53–79 (2017). 
49. Nimmerjahn, A. Resting Microglial Cells Are Highly Dynamic Surveillants of Brain Parenchyma in 
Vivo. Science 308, 1314–1318 (2005). 
50. Wake, H., Moorhouse, A. J., Jinno, S., Kohsaka, S. & Nabekura, J. Resting microglia directly 
monitor the functional state of synapses in vivo and determine the fate of ischemic terminals. J. 
Neurosci. 29, 3974–3980 (2009). 
51. Davalos, D. et al. ATP mediates rapid microglial response to local brain injury in vivo. Nat. 
Neurosci. 8, 752–758 (2005). 
52. Inoue, K. Purinergic systems in microglia. Cell. Mol. Life Sci. 65, 3074–3080 (2008). 
53. Mercier, F. E. & Scadden, D. T. Not All Created Equal: Lineage Hard-Wiring in the Production of 
Blood. Cell 163, 1568–1570 (2015). 
54. Kondo, M., Weissman, I. L. & Akashi, K. Identification of clonogenic common lymphoid 
progenitors in mouse bone marrow. Cell 91, 661–672 (1997). 
55. Akashi, K., Traver, D., Miyamoto, T. & Weissman, I. L. A clonogenic common myeloid progenitor 
that gives rise to all myeloid lineages. Nature 404, 193–197 (2000). 
56. Fogg, D. K. et al. A clonogenic bone marrow progenitor specific for macrophages and dendritic 
cells. Science 311, 83–87 (2006). 
57. Hettinger, J. et al. Origin of monocytes and macrophages in a committed progenitor. Nat Immunol 
14, 821–830 (2013). 
58. Paul, F. et al. Transcriptional Heterogeneity and Lineage Commitment in Myeloid Progenitors. Cell 
163, 1663–1677 (2015). 
59. Perié, L., Duffy, K. R., Kok, L., de Boer, R. J. & Schumacher, T. N. The Branching Point in 
Erythro-Myeloid Differentiation. Cell 163, 1655–1662 (2015). 
60. Laurenti, E. & Göttgens, B. From haematopoietic stem cells to complex differentiation landscapes. 
Nature 553, 418–426 (2018). 
61. Monticelli, S. & Natoli, G. Transcriptional determination and functional specificity of myeloid 
 36 
cells: making sense of diversity. Nat. Rev. Immunol 17, 595–607 (2017). 
62. Dahl, R. et al. Regulation of macrophage and neutrophil cell fates by the PU.1:C/EBPalpha ratio 
and granulocyte colony-stimulating factor. Nat Immunol 4, 1029–1036 (2003). 
63. Tamura, T., Nagamura-Inoue, T., Shmeltzer, Z., Kuwata, T. & Ozato, K. ICSBP directs bipotential 
myeloid progenitor cells to differentiate into mature macrophages. Immunity 13, 155–165 (2000). 
64. Person, R. E. et al. Mutations in proto-oncogene GFI1 cause human neutropenia and target ELA2. 
Nat. Genet. 34, 308–312 (2003). 
65. Olsson, A. et al. Single-cell analysis of mixed-lineage states leading to a binary cell fate choice. 
Nature 537, 698–702 (2016). 
66. Rieger, M. A., Hoppe, P. S., Smejkal, B. M., Eitelhuber, A. C. & Schroeder, T. Hematopoietic 
Cytokines Can Instruct Lineage Choice. Science 325, 217–218 (2009). 
67. Dai, X.-M. et al. Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results 
in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, 
and reproductive defects. Blood 99, 111–120 (2002). 
68. Lieschke, G. J. et al. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, 
granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. 
Blood 84, 1737–1746 (1994). 
69. Helft, J. et al. GM-CSF Mouse Bone Marrow Cultures Comprise a Heterogeneous Population of 
CD11c(+)MHCII(+) Macrophages and Dendritic Cells. Immunity 42, 1197–1211 (2015). 
70. Lutz, M. B., Strobl, H., Schuler, G. & Romani, N. GM-CSF Monocyte-Derived Cells and 
Langerhans Cells As Part of the Dendritic Cell Family. Front Immunol 8, 1388 (2017). 
71. Becher, B., Tugues, S. & Greter, M. GM-CSF: From Growth Factor to Central Mediator of Tissue 
Inflammation. Immunity 45, 963–973 (2016). 
72. Mossadegh-Keller, N. et al. M-CSF instructs myeloid lineage fate in single haematopoietic stem 
cells. Nature 497, 239–243 (2013). 
73. Passlick, B., Flieger, D. & Ziegler-Heitbrock, H. W. Identification and characterization of a novel 
monocyte subpopulation in human peripheral blood. Blood 74, 2527–2534 (1989). 
74. Ginhoux, F. & Jung, S. Monocytes and macrophages: developmental pathways and tissue 
homeostasis. Nat. Rev. Immunol 14, 392–404 (2014). 
75. Serbina, N. V. & Pamer, E. G. Monocyte emigration from bone marrow during bacterial infection 
requires signals mediated by chemokine receptor CCR2. Nat Immunol 7, 311–317 (2006). 
76. Shi, C. et al. Bone marrow mesenchymal stem and progenitor cells induce monocyte emigration in 
response to circulating toll-like receptor ligands. Immunity 34, 590–601 (2011). 
77. Yona, S. et al. Fate Mapping Reveals Origins and Dynamics of Monocytes and Tissue Macrophages 
under Homeostasis. Immunity 38, 79–91 (2013). 
78. Mildner, A. et al. Genomic Characterization of Murine Monocytes Reveals C/EBPβ Transcription 
Factor Dependence of Ly6C- Cells. Immunity 46, 849–862.e7 (2017). 
79. Menezes, S. et al. The Heterogeneity of Ly6Chi Monocytes Controls Their Differentiation into 
iNOS+ Macrophages or Monocyte-Derived Dendritic Cells. Immunity 45, 1205–1218 (2016). 
80. Yáñez, A. et al. Granulocyte-Monocyte Progenitors and Monocyte-Dendritic Cell Progenitors 
Independently Produce Functionally Distinct Monocytes. Immunity 47, 890–902.e4 (2017). 
81. Satoh, T. et al. Identification of an atypical monocyte and committed progenitor involved in 
fibrosis. Nature 541, 96–101 (2017). 
82. Schulz, C. et al. A Lineage of Myeloid Cells Independent of Myb and Hematopoietic Stem Cells. 
Science 336, 86–90 (2012). 
83. Bogunovic, M. et al. Origin of the lamina propria dendritic cell network. Immunity 31, 513–525 
(2009). 
84. Bain, C. C. et al. Constant replenishment from circulating monocytes maintains the macrophage 
pool in the intestine of adult mice. Nat Immunol 15, 929–937 (2014). 
85. Grainger, J. R., Konkel, J. E., Zangerle-Murray, T. & Shaw, T. N. Macrophages in gastrointestinal 
homeostasis and inflammation. Pflugers Arch. 469, 527–539 (2017). 
86. Bain, C. C. et al. Resident and pro-inflammatory macrophages in the colon represent alternative 
context-dependent fates of the same Ly6Chi monocyte precursors. Mucosal Immunol 6, 498–510 
(2013). 
87. Smythies, L. E. et al. Human intestinal macrophages display profound inflammatory anergy despite 
avid phagocytic and bacteriocidal activity. J. Clin. Invest. 115, 66–75 (2005). 
88. Zigmond, E. et al. Macrophage-restricted interleukin-10 receptor deficiency, but not IL-10 
deficiency, causes severe spontaneous colitis. Immunity 40, 720–733 (2014). 
89. Tamoutounour, S. et al. Origins and functional specialization of macrophages and of conventional 
and monocyte-derived dendritic cells in mouse skin. Immunity 39, 925–938 (2013). 
90. Calderon, B. et al. The pancreas anatomy conditions the origin and properties of resident 
macrophages. J. Exp. Med. 212, 1497–1512 (2015). 
91. Mossadegh-Keller, N. et al. Developmental origin and maintenance of distinct testicular 
  37 
macrophage populations. J. Exp. Med. 214, 2829–2841 (2017). 
92. Bain, C. C. et al. Long-lived self-renewing bone marrow-derived macrophages displace embryo-
derived cells to inhabit adult serous cavities. Nature Communications 7, 11852 (2016). 
93. Molawi, K. et al. Progressive replacement of embryo-derived cardiac macrophages with age. J. Exp. 
Med. 211, 2151–2158 (2014). 
94. Epelman, S. et al. Embryonic and adult-derived resident cardiac macrophages are maintained 
through distinct mechanisms at steady state and during inflammation. Immunity 40, 91–104 (2014). 
95. Heidt, T. et al. Differential contribution of monocytes to heart macrophages in steady-state and after 
myocardial infarction. Circulation Research 115, 284–295 (2014). 
96. Swirski, F. K., Robbins, C. S. & Nahrendorf, M. Development and Function of Arterial and Cardiac 
Macrophages. Trends Immunol. 37, 32–40 (2016). 
97. Shi, C. & Pamer, E. G. Monocyte recruitment during infection and inflammation. Nat. Rev. 
Immunol 11, 762–774 (2011). 
98. Blériot, C. et al. Liver-resident macrophage necroptosis orchestrates type 1 microbicidal 
inflammation and type-2-mediated tissue repair during bacterial infection. Immunity 42, 145–158 
(2015). 
99. Machiels, B. et al. A gammaherpesvirus provides protection against allergic asthma by inducing the 
replacement of resident alveolar macrophages with regulatory monocytes. Nat Immunol 18, 1310–
1320 (2017). 
100. Arnold, L. et al. Inflammatory monocytes recruited after skeletal muscle injury switch into 
antiinflammatory macrophages to support myogenesis. J. Exp. Med 204, 1057–1069 (2007). 
101. Zigmond, E. et al. Infiltrating monocyte-derived macrophages and resident kupffer cells display 
different ontogeny and functions in acute liver injury. J. Immunol. 193, 344–353 (2014). 
102. Dewald, O. et al. CCL2/Monocyte Chemoattractant Protein-1 regulates inflammatory responses 
critical to healing myocardial infarcts. Circulation Research 96, 881–889 (2005). 
103. Nahrendorf, M. et al. The healing myocardium sequentially mobilizes two monocyte subsets with 
divergent and complementary functions. J. Exp. Med. 204, 3037–3047 (2007). 
104. Sager, H. B., Kessler, T. & Schunkert, H. Monocytes and macrophages in cardiac injury and repair. 
J Thorac Dis 9, S30–S35 (2017). 
105. Hulsmans, M. et al. Cardiac macrophages promote diastolic dysfunction. J. Exp. Med. 215, 423–
440 (2018). 
106. Davoust, N., Vuaillat, C., Androdias, G. & Nataf, S. From bone marrow to microglia: barriers and 
avenues. Trends Immunol. 29, 227–234 (2008). 
107. Dietrich, J. et al. Bone marrow drives central nervous system regeneration after radiation injury. J. 
Clin. Invest. 128, 281–293 (2018). 
108. ElAli, A. & Jean LeBlanc, N. The Role of Monocytes in Ischemic Stroke Pathobiology: New 
Avenues to Explore. Front Aging Neurosci 8, 29 (2016). 
109. Varvel, N. H. et al. Infiltrating monocytes promote brain inflammation and exacerbate neuronal 
damage after status epilepticus. Proc. Natl. Acad. Sci. U.S.A. 113, E5665–74 (2016). 
110. Morganti, J. M. et al. CCR2 antagonism alters brain macrophage polarization and ameliorates 
cognitive dysfunction induced by traumatic brain injury. J. Neurosci. 35, 748–760 (2015). 
111. Makinde, H. M., Cuda, C. M., Just, T. B., Perlman, H. R. & Schwulst, S. J. Nonclassical Monocytes 
Mediate Secondary Injury, Neurocognitive Outcome, and Neutrophil Infiltration after Traumatic 
Brain Injury. J. Immunol. 199, 3583–3591 (2017). 
112. Lund, H., Pieber, M. & Harris, R. A. Lessons Learned about Neurodegeneration from Microglia and 
Monocyte Depletion Studies. Front Aging Neurosci 9, 234 (2017). 
113. Shechter, R. et al. Recruitment of beneficial M2 macrophages to injured spinal cord is orchestrated 
by remote brain choroid plexus. Immunity 38, 555–569 (2013). 
114. Scott, C. L. et al. Bone marrow-derived monocytes give rise to self-renewing and fully 
differentiated Kupffer cells. Nature Communications 7, 10321 (2016). 
115. van de Laar, L. et al. Yolk Sac Macrophages, Fetal Liver, and Adult Monocytes Can Colonize an 
Empty Niche and Develop into Functional Tissue-Resident Macrophages. Immunity 44, 755–768 
(2016). 
116. Bruttger, J. et al. Genetic Cell Ablation Reveals Clusters of Local Self-Renewing Microglia in the 
Mammalian Central Nervous System. Immunity 43, 92–106 (2015). 
117. Huang, Y. et al. Repopulated microglia are solely derived from the proliferation of residual 
microglia after acute depletion. Nat. Neurosci. 21, 530–540 (2018). 
118. Buttgereit, A. et al. Sall1 is a transcriptional regulator defining microglia identity and function. Nat 
Immunol 17, 1397–1406 (2016). 
119. Grathwohl, S. A. et al. Formation and maintenance of Alzheimer's disease β-amyloid plaques in the 
absence of microglia. Nat. Neurosci. 12, 1361–1363 (2009). 
120. Varvel, N. H. et al. Microglial repopulation model reveals a robust homeostatic process for 
replacing CNS myeloid cells. Proc. Natl. Acad. Sci. U.S.A. 109, 18150–18155 (2012). 
 38 
121. Prokop, S. et al. Impact of peripheral myeloid cells on amyloid-β pathology in Alzheimer's disease-
like mice. J. Exp. Med. 212, 1811–1818 (2015). 
122. Amit, I., Winter, D. R. & Jung, S. The role of the local environment and epigenetics in shaping 
macrophage identity and their effect on tissue homeostasis. Nat Immunol 17, 18–25 (2015). 
123. Perdiguero, E. G. & Geissmann, F. The development and maintenance of resident macrophages. Nat 
Immunol 17, 2–8 (2016). 
124. Mass, E. et al. Specification of tissue-resident macrophages during organogenesis. Science 353, 
aaf4238–aaf4238 (2016). 
125. Schneider, C. et al. Induction of the nuclear receptor PPAR-γ by the cytokine GM-CSF is critical 
for the differentiation of fetal monocytes into alveolar macrophages. Nat Immunol 15, 1026–1037 
(2014). 
126. Kohyama, M. et al. Role for Spi-C in the development of red pulp macrophages and splenic iron 
homeostasis. Nature 457, 318–321 (2009). 
127. Fainaru, O. et al. Runx3 regulates mouse TGF-beta-mediated dendritic cell function and its absence 
results in airway inflammation. EMBO J. 23, 969–979 (2004). 
128. Okabe, Y. & Medzhitov, R. Tissue-specific signals control reversible program of localization and 
functional polarization of macrophages. Cell 157, 832–844 (2014). 
129. Rosas, M. et al. The transcription factor Gata6 links tissue macrophage phenotype and proliferative 
renewal. Science 344, 645–648 (2014). 
130. Lavin, Y. et al. Tissue-resident macrophage enhancer landscapes are shaped by the local 
microenvironment. Cell 159, 1312–1326 (2014). 
131. T'Jonck, W., Guilliams, M. & Bonnardel, J. Niche signals and transcription factors involved in 
tissue-resident macrophage development. Cell. Immunol. (2018). 
doi:10.1016/j.cellimm.2018.02.005 
132. Haldar, M. et al. Heme-mediated SPI-C induction promotes monocyte differentiation into iron-
recycling macrophages. Cell 156, 1223–1234 (2014). 
133. Guilliams, M. et al. Alveolar macrophages develop from fetal monocytes that differentiate into 
long-lived cells in the first week of life via GM-CSF. J. Exp. Med. 210, 1977–1992 (2013). 
134. Yu, X. et al. The Cytokine TGF-β Promotes the Development and Homeostasis of Alveolar 
Macrophages. Immunity 47, 903–912 (2017). 
135. Butovsky, O. et al. Identification of a unique TGF-β–dependent molecular and functional signature 
in microglia. Nat. Neurosci. 17, 131–143 (2013). 
136. Shi, M. et al. Latent TGF-β structure and activation. Nature 474, 343–349 (2011). 
137. Travis, M. A. & Sheppard, D. TGF-β Activation and Function in Immunity. Annu. Rev. Immunol. 
32, 51–82 (2014). 
138. Town, T. et al. Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like 
pathology. Nature Med. 14, 681–687 (2008). 
139. Nurgazieva, D. et al. TGF-β1, but not bone morphogenetic proteins, activates Smad1/5 pathway in 
primary human macrophages and induces expression of proatherogenic genes. J. Immunol. 194, 
709–718 (2015). 
140. Zhang, Y. E. Non-Smad pathways in TGF-beta signaling. Cell Res. 19, 128–139 (2009). 
141. Wan, M. et al. Smad4 protein stability is regulated by ubiquitin ligase SCF beta-TrCP1. Journal of 
Biological Chemistry 279, 14484–14487 (2004). 
142. Annes, J. P., Munger, J. S. & Rifkin, D. B. Making sense of latent TGFbeta activation. Journal of 
Cell Science 116, 217–224 (2003). 
143. Shull, M. M. et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results 
in multifocal inflammatory disease. Nature 359, 693–699 (1992). 
144. Kulkarni, A. B. et al. Transforming growth factor beta 1 null mutation in mice causes excessive 
inflammatory response and early death. Proc. Natl. Acad. Sci. U.S.A. 90, 770–774 (1993). 
145. Gosselin, D. et al. Environment drives selection and function of enhancers controlling tissue-
specific macrophage identities. Cell 159, 1327–1340 (2014). 
146. Borkowski, T. A., Letterio, J. J., Farr, A. G. & Udey, M. C. A role for endogenous transforming 
growth factor beta 1 in Langerhans cell biology: the skin of transforming growth factor beta 1 null 
mice is devoid of epidermal Langerhans cells. J. Exp. Med 184, 2417–2422 (1996). 
147. Kaplan, D. H. et al. Autocrine/paracrine TGFbeta1 is required for the development of epidermal 
Langerhans cells. J. Exp. Med. 204, 2545–2552 (2007). 
148. Zahner, S. P. et al. Conditional deletion of TGF-βR1 using Langerin-Cre mice results in Langerhans 
cell deficiency and reduced contact hypersensitivity. J. Immunol. 187, 5069–5076 (2011). 
149. Ben-Nun, A., Wekerle, H. & Cohen, I. R. Vaccination against autoimmune encephalomyelitis with 
T-lymphocyte line cells reactive against myelin basic protein. Nature 292, 60–61 (1981). 
150. Greter, M. et al. Dendritic cells permit immune invasion of the CNS in an animal model of multiple 
sclerosis. Nature Med. 11, 328–334 (2005). 
151. Schläger, C. et al. Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid. 
  39 
Nature 530, 349–353 (2016). 
152. Ford, A. L. Microglia induce CD4 T lymphocyte final effector function and death. J. Exp. Med 184, 
1737–1745 (1996). 
153. Becher, B., Spath, S. & Goverman, J. Cytokine networks in neuroinflammation. Nat. Rev. Immunol 
17, 49–59 (2017). 
154. Ajami, B., Bennett, J. L., Krieger, C., McNagny, K. M. & Rossi, F. M. V. Infiltrating monocytes 
trigger EAE progression, but do not contribute to the resident microglia pool. Nat. Neurosci. 14, 
1142–1149 (2011). 
155. Izikson, L., Klein, R. S., Charo, I. F., Weiner, H. L. & Luster, A. D. Resistance to experimental 
autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2. J. Exp. Med 
192, 1075–1080 (2000). 
156. Fife, B. T., Huffnagle, G. B., Kuziel, W. A. & Karpus, W. J. CC chemokine receptor 2 is critical for 
induction of experimental autoimmune encephalomyelitis. J. Exp. Med 192, 899–905 (2000). 
157. Mildner, A. et al. CCR2+Ly-6Chi monocytes are crucial for the effector phase of autoimmunity in 
the central nervous system. Brain 132, 2487–2500 (2009). 
158. Croxford, A. L. et al. The Cytokine GM-CSF Drives the Inflammatory Signature of CCR2+ 
Monocytes and Licenses Autoimmunity. Immunity 43, 502–514 (2015). 
159. Spath, S. et al. Dysregulation of the Cytokine GM-CSF Induces Spontaneous Phagocyte Invasion 
and Immunopathology in the Central Nervous System. Immunity 46, 245–260 (2017). 
160. Heppner, F. L. et al. Experimental autoimmune encephalomyelitis repressed by microglial paralysis. 
Nature Med. 11, 146–152 (2005). 
161. Becher, B. The Clinical Course of Experimental Autoimmune Encephalomyelitis and Inflammation 
Is Controlled by the Expression of CD40 within the Central Nervous System. J. Exp. Med 193, 967–
974 (2001). 
162. Goldmann, T. et al. A new type of microglia gene targeting shows TAK1 to be pivotal in CNS 
autoimmune inflammation. Nat. Neurosci. 16, 1618–1626 (2013). 
163. Yamasaki, R. et al. Differential roles of microglia and monocytes in the inflamed central nervous 
system. J. Exp. Med 211, 1533–1549 (2014). 
164. Hagemeyer, N. et al. Microglia contribute to normal myelinogenesis and to oligodendrocyte 
progenitor maintenance during adulthood. Acta Neuropathol 134, 441–458 (2017). 
165. Safaiyan, S. et al. Age-related myelin degradation burdens the clearance function of microglia 
during aging. Nat. Neurosci. 19, 995–998 (2016). 
166. Miron, V. E. et al. M2 microglia and macrophages drive oligodendrocyte differentiation during 
CNS remyelination. Nat. Neurosci. 16, 1211–1218 (2013). 
167. Jucker, M. & Walker, L. C. Self-propagation of pathogenic protein aggregates in neurodegenerative 
diseases. Nature 501, 45–51 (2013). 
168. Brettschneider, J., Del Tredici, K., Lee, V. M. Y. & Trojanowski, J. Q. Spreading of pathology in 
neurodegenerative diseases: a focus on human studies. Nat Rev Neurosci 16, 109–120 (2015). 
169. Braak, H. & Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 
82, 239–259 (1991). 
170. Thal, D. R. et al. Sequence of Abeta-protein deposition in the human medial temporal lobe. Journal 
of Neuropathology and Experimental Neurology 59, 733–748 (2000). 
171. Clavaguera, F. et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell 
Biol. 11, 909–913 (2009). 
172. Meyer-Luehmann, M. et al. Exogenous induction of cerebral beta-amyloidogenesis is governed by 
agent and host. Science 313, 1781–1784 (2006). 
173. Alzheimer, A., Stelzmann, R. A., Schnitzlein, H. N. & Murtagh, F. R. An English translation of 
Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde". Clinical anatomy (New 
York, N.Y.) 8, 429–431 (1995). 
174. Gosselin, D. et al. An environment-dependent transcriptional network specifies human microglia 
identity. Science 356, eaal3222 (2017). 
175. Sarlus, H. & Heneka, M. T. Microglia in Alzheimer's disease. J. Clin. Invest. 127, 3240–3249 
(2017). 
176. Varvel, N. H. et al. Replacement of brain-resident myeloid cells does not alter cerebral amyloid-β 
deposition in mouse models of Alzheimer's disease. J. Exp. Med. 212, 1803–1809 (2015). 
177. Spangenberg, E. E. et al. Eliminating microglia in Alzheimer's mice prevents neuronal loss without 
modulating amyloid-β pathology. Brain 139, 1265–1281 (2016). 
178. Yuan, P. et al. TREM2 Haplodeficiency in Mice and Humans Impairs the Microglia Barrier 
Function Leading to Decreased Amyloid Compaction and Severe Axonal Dystrophy. Neuron 92, 
252–264 (2016). 
179. Guerreiro, R. et al. TREM2 variants in Alzheimer's disease. N Engl J Med 368, 117–127 (2013). 
180. Jonsson, T. et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med 
368, 107–116 (2013). 
 40 
181. Bellucci, A. et al. Induction of inflammatory mediators and microglial activation in mice transgenic 
for mutant human P301S tau protein. The American Journal of Pathology 165, 1643–1652 (2004). 
182. Yoshiyama, Y. et al. Synapse Loss and Microglial Activation Precede Tangles in a P301S 
Tauopathy Mouse Model. Neuron 53, 337–351 (2007). 
183. Lee, D. C. et al. LPS- induced inflammation exacerbates phospho-tau pathology in rTg4510 mice. 
Journal of Neuroinflammation 7, 56 (2010). 
184. Asai, H. et al. Accelerated Neurodegeneration and Neuroinflammation in Transgenic Mice 
Expressing P301L Tau Mutant and Tau-Tubulin Kinase 1. The American Journal of Pathology 184, 
808–818 (2014). 
185. Asai, H. et al. Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat. 
Neurosci. 18, 1584–1593 (2015). 
186. Luo, W. et al. Microglial internalization and degradation of pathological tau is enhanced by an anti-
tau monoclonal antibody. Sci. Rep. 5, 11161 (2015). 
187. Bolós, M. et al. Direct Evidence of Internalization of Tau by Microglia In Vitro and In Vivo. J. 
Alzheimers Dis. 50, 77–87 (2016). 
188. Venegas, C. et al. Microglia-derived ASC specks cross-seed amyloid-β in Alzheimer's disease. 
Nature 552, 355–361 (2017). 
189. Bhaskar, K. et al. Regulation of Tau Pathology by the Microglial Fractalkine Receptor. Neuron 68, 
19–31 (2010). 
190. Maphis, N. et al. Reactive microglia drive tau pathology and contribute to the spreading of 
pathological tau in the brain. Brain 138, 1738–1755 (2015). 
191. Kitazawa, M., Oddo, S., Yamasaki, T. R., Green, K. N. & LaFerla, F. M. Lipopolysaccharide-
induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway 
in a transgenic model of Alzheimer's disease. J. Neurosci. 25, 8843–8853 (2005). 
192. Gutierrez, A. & Vitorica, J. Toward a New Concept of Alzheimer's Disease Models: A Perspective 
from Neuroinflammation. J. Alzheimers Dis. 15, 1–10 (2018). 
193. Sanchez-Mejias, E. et al. Soluble phospho-tau from Alzheimer's disease hippocampus drives 
microglial degeneration. Acta Neuropathol 132, 897–916 (2016). 
194. Streit, W. J., Braak, H., Xue, Q.-S. & Bechmann, I. Dystrophic (senescent) rather than activated 
microglial cells are associated with tau pathology and likely precede neurodegeneration in 
Alzheimer’s disease. Acta Neuropathol 118, 475–485 (2009). 
195. Streit, W. J. & Xue, Q.-S. Human CNS immune senescence and neurodegeneration. Current 
Opinion in Immunology 29, 93–96 (2014). 
196. Rodriguez-Callejas, J. D., Fuchs, E. & Perez-Cruz, C. Evidence of Tau Hyperphosphorylation and 
Dystrophic Microglia in the Common Marmoset. Front Aging Neurosci 8, 315 (2016). 
197. Feil, S., Valtcheva, N. & Feil, R. Inducible Cre mice. Methods Mol. Biol. 530, 343–363 (2009). 
198. Kagan, E. & Hartmann, D. P. Elimination of macrophages with silica and asbestos. Meth. Enzymol. 
108, 325–335 (1984). 
199. van Rooijen, N. The liposome-mediated macrophage ‘suicide’ technique. J. Immunol. Methods 124, 
1–6 (1989). 
200. Buch, T. et al. A Cre-inducible diphtheria toxin receptor mediates cell lineage ablation after toxin 
administration. Nat Meth 2, 419–426 (2005). 
201. Duffield, J. S. et al. Selective depletion of macrophages reveals distinct, opposing roles during liver 
injury and repair. J. Clin. Invest. 115, 56–65 (2005). 
202. Wu, S., Wu, Y. & Capecchi, M. R. Motoneurons and oligodendrocytes are sequentially generated 
from neural stem cells but do not appear to share common lineage-restricted progenitors in vivo. 
Development 133, 581–590 (2006). 
203. Li, M. O., Sanjabi, S. & Flavell, R. A. Transforming growth factor-beta controls development, 
homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. 
Immunity 25, 455–471 (2006). 
204. Clausen, B. E., Burkhardt, C., Reith, W., Renkawitz, R. & Förster, I. Conditional gene targeting in 
macrophages and granulocytes using LysMcre mice. Transgenic Res. 8, 265–277 (1999). 
205. Becher, B. et al. High-dimensional analysis of the murine myeloid cell system. Nat Immunol 15, 
1181–1189 (2014). 
206. Guilliams, M. et al. Unsupervised High-Dimensional Analysis Aligns Dendritic Cells across 
Tissues and Species. Immunity 45, 669–684 (2016). 
207. Korin, B. et al. High-dimensional, single-cell characterization of the brain's immune compartment. 
Nat. Neurosci. 20, 1300–1309 (2017). 
208. Ajami, B. et al. Single-cell mass cytometry reveals distinct populations of brain myeloid cells in 
mouse neuroinflammation and neurodegeneration models. Nat. Neurosci. 21, 541–551 (2018). 
209. Caravagna, C. et al. Diversity of innate immune cell subsets across spatial and temporal scales in an 
EAE mouse model. Sci. Rep. 8, 5146 (2018). 
210. Parsa, R. et al. Adoptive Transfer of Immunomodulatory M2 Macrophages Prevents Type 1 
  41 
Diabetes in NOD Mice. Diabetes 61, 2881–2892 (2012). 
211. Zhang, X.-M., Lund, H., Mia, S., Parsa, R. & Harris, R. A. Adoptive transfer of cytokine-induced 
immunomodulatory adult microglia attenuates experimental autoimmune encephalomyelitis in 
DBA/1 mice. Glia 62, 804–817 (2014). 
212. Malipiero, U. et al. TGFbeta receptor II gene deletion in leucocytes prevents cerebral vasculitis in 
bacterial meningitis. Brain 129, 2404–2415 (2006). 
213. Novitskiy, S. V. et al. Deletion of TGF-β signaling in myeloid cells enhances their anti-tumorigenic 
properties. Journal of Leukocyte Biology 92, 641–651 (2012). 
214. Li, J. et al. Myeloid TGF-β signaling contributes to colitis-associated tumorigenesis in mice. 
Carcinogenesis 34, 2099–2108 (2013). 
215. Racke, M. K. et al. Prevention and treatment of chronic relapsing experimental allergic 
encephalomyelitis by transforming growth factor-beta 1. J Immunol 146, 3012–3017 (1991). 
216. Racke, M. K. et al. Long-term treatment of chronic relapsing experimental allergic 
encephalomyelitis by transforming growth factor-β2. J Neuroimmunol 46, 175–183 (1993). 
217. Johns, L. D. & Sriram, S. Experimental allergic encephalomyelitis: Neutralizing antibody to TGFβ1 
enhances the clinical severity of the disease. J Neuroimmunol 47, 1–7 (1993). 
218. Luo, J. et al. Glia-dependent TGF-β signaling, acting independently of the TH17 pathway, is critical 
for initiation of murine autoimmune encephalomyelitis. J. Clin. Invest. 117, 3306–3315 (2007). 
219. Lanz, T. V. et al. Angiotensin II sustains brain inflammation in mice via TGF-β. J. Clin. Invest. 120, 
2782–2794 (2010). 
220. Speck, S. et al. TGF-β Signaling Initiated in Dendritic Cells Instructs Suppressive Effects on Th17 
Differentiation at the Site of Neuroinflammation. PLoS ONE 9, e102390 (2014). 
221. Ramalingam, R. et al. Dendritic Cell-Specific Disruption of TGF-β Receptor II Leads to Altered 
Regulatory T Cell Phenotype and Spontaneous Multiorgan Autoimmunity. J Immunol 189, 3878–
3893 (2012). 
222. Laouar, Y. et al. TGF-beta signaling in dendritic cells is a prerequisite for the control of 
autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U.S.A. 105, 10865–10870 (2008). 
223. Waisman, A., Ginhoux, F., Greter, M. & Bruttger, J. Homeostasis of Microglia in the Adult Brain: 
Review of Novel Microglia Depletion Systems. Trends Immunol. 36, 625–636 (2015). 
224. Cronk, J. C. et al. Peripherally derived macrophages can engraft the brain independent of irradiation 
and maintain an identity distinct from microglia. J. Exp. Med. (2018). doi:10.1084/jem.20180247 
225. Ma, J., Yu, J.-T. & Tan, L. MS4A Cluster in Alzheimer's Disease. Mol. Neurobiol. 51, 1240–1248 
(2015). 
226. Wendeln, A.-C. et al. Innate immune memory in the brain shapes neurological disease hallmarks. 
Nature 556, 332–338 (2018). 
227. Wes, P. D., Holtman, I. R., Boddeke, E. W. G. M., Möller, T. & Eggen, B. J. L. Next generation 
transcriptomics and genomics elucidate biological complexity of microglia in health and disease. 
Glia 64, 197–213 (2015). 
228. Gosselin, D. & Glass, C. K. Epigenomics of macrophages. Immunol. Rev. 262, 96–112 (2014). 
229. Wahl, S. M. et al. Transforming growth factor type beta induces monocyte chemotaxis and growth 
factor production. Proc. Natl. Acad. Sci. U.S.A. 84, 5788–5792 (1987). 
230. Smythies, L. E. et al. Mucosal IL-8 and TGF-beta recruit blood monocytes: evidence for cross-talk 
between the lamina propria stroma and myeloid cells. Journal of Leukocyte Biology 80, 492–499 
(2006). 
231. Wahl, S. M., Allen, J. B., Weeks, B. S., Wong, H. L. & Klotman, P. E. Transforming growth factor 
beta enhances integrin expression and type IV collagenase secretion in human monocytes. Proc. 
Natl. Acad. Sci. U.S.A. 90, 4577–4581 (1993). 
232. Krasemann, S. et al. The TREM2-APOE Pathway Drives the Transcriptional Phenotype of 
Dysfunctional Microglia in Neurodegenerative Diseases. Immunity 47, 566–581.e9 (2017). 
233. Efthymiou, A. G. & Goate, A. M. Late onset Alzheimer's disease genetics implicates microglial 
pathways in disease risk. Molecular Neurodegeneration 12, 43 (2017). 
234. Swardfager, W. et al. A Meta-Analysis of Cytokines in Alzheimer's Disease. Biological Psychiatry 
68, 930–941 (2010). 
235. Grabert, K. et al. Microglial brain region-dependent diversity and selective regional sensitivities to 
aging. Nat. Neurosci. 19, 504–516 (2016). 
236. Acker, C. M., Forest, S. K., Zinkowski, R., Davies, P. & d'Abramo, C. Sensitive quantitative assays 
for tau and phospho-tau in transgenic mouse models. Neurobiology of Aging 34, 338–350 (2013). 
237. Andorfer, C. et al. Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human 
tau isoforms. J. Neurosci. 25, 5446–5454 (2005). 
238. Polydoro, M., Acker, C. M., Duff, K., Castillo, P. E. & Davies, P. Age-dependent impairment of 
cognitive and synaptic function in the htau mouse model of tau pathology. J. Neurosci. 29, 10741–
10749 (2009). 
239. Phillips, M., Boman, E., Österman, H., Willhite, D. & Laska, M. Olfactory and Visuospatial 
 42 
Learning and Memory Performance in Two Strains of Alzheimer's Disease Model Mice—A 
Longitudinal Study. PLoS ONE 6, e19567 (2011). 
240. Zrzavy, T. et al. Loss of ‘homeostatic’ microglia and patterns of their activation in active multiple 
sclerosis. Brain 140, 1900–1913 (2017). 
241. Ransohoff, R. M. A polarizing question: do M1 and M2 microglia exist? Nat. Neurosci. 19, 987–
991 (2016). 
242. Wong, K. et al. Mice deficient in NRROS show abnormal microglial development and neurological 
disorders. Nat Immunol 18, 633–641 (2017). 
243. Mass, E. et al. A somatic mutation in erythro-myeloid progenitors causes neurodegenerative 
disease. Nature 549, 389–393 (2017). 
244. Frakes, A. E. et al. Microglia induce motor neuron death via the classical NF-κB pathway in 
amyotrophic lateral sclerosis. Neuron 81, 1009–1023 (2014). 
245. Friedman, B. A. et al. Diverse Brain Myeloid Expression Profiles Reveal Distinct Microglial 
Activation States and Aspects of Alzheimer’s Disease Not Evident in Mouse Models. Cell Reports 
22, 832–847 (2018). 
 
